<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005993.pub2" GROUP_ID="DEMENTIA" ID="058805090610151552" MERGED_FROM="" MODIFIED="2010-06-10 15:01:57 +0200" MODIFIED_BY="Sue Marcus" REVIEW_NO="129" REVMAN_SUB_VERSION="5.0.24" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2010-06-10 15:01:57 +0200" MODIFIED_BY="Sue Marcus">
<TITLE>Procaine treatments for cognition and dementia</TITLE>
<CONTACT MODIFIED="2010-06-10 15:01:57 +0200" MODIFIED_BY="Sue Marcus"><PERSON ID="13078" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Szabolcs</FIRST_NAME><LAST_NAME>Szatmári</LAST_NAME><POSITION>Neurologist</POSITION><EMAIL_1>szabolcs.szatmari@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>University of Medicine and Pharmacy Tg. Mures</ORGANISATION><ADDRESS_1>Ghe Marinescu 38</ADDRESS_1><CITY>Targu Mures</CITY><ZIP>540000</ZIP><COUNTRY CODE="RO">Romania</COUNTRY><PHONE_1>0040265-212111</PHONE_1><FAX_1>0040265-214510</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-06-10 15:01:57 +0200" MODIFIED_BY="Sue Marcus"><PERSON ID="13078" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Szabolcs</FIRST_NAME><LAST_NAME>Szatmári</LAST_NAME><POSITION>Neurologist</POSITION><EMAIL_1>szabolcs.szatmari@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>University of Medicine and Pharmacy Tg. Mures</ORGANISATION><ADDRESS_1>Ghe Marinescu 38</ADDRESS_1><CITY>Targu Mures</CITY><ZIP>540000</ZIP><COUNTRY CODE="RO">Romania</COUNTRY><PHONE_1>0040265-212111</PHONE_1><FAX_1>0040265-214510</FAX_1></ADDRESS></PERSON><PERSON ID="7186" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Dániel</FIRST_NAME><LAST_NAME>Bereczki</LAST_NAME><SUFFIX>MD, PhD, DSc</SUFFIX><POSITION>Professor of Neurology</POSITION><EMAIL_1>bereczki@neur.sote.hu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Semmelweis University</ORGANISATION><ADDRESS_1>Balassa u. 6.</ADDRESS_1><CITY>Budapest</CITY><ZIP>H-1083</ZIP><COUNTRY CODE="HU">Hungary</COUNTRY><PHONE_1>+36 1 210 0337</PHONE_1><FAX_1>+36 1 210 1368</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-05-26 16:27:21 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="28" MONTH="4" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="16" MONTH="4" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="16" MONTH="11" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2010-04-28 11:56:23 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-04-28 11:56:23 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="4" YEAR="2010"/>
<DESCRIPTION>
<P>An update search was performed for this review on 16 April 2010. No new studies were identified for either inclusion or exclusion within the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-06-11 15:21:44 +0100" MODIFIED_BY="Helen Collins"/>
<SOURCES_OF_SUPPORT MODIFIED="2008-07-02 16:18:54 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2008-07-02 16:18:54 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2008-07-02 16:18:54 +0100" MODIFIED_BY="[Empty name]">
<NAME>Hungarian-Romanian S&amp;T Cooperation Programme Ro19/2005 and Ro 30/2007</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION>
<P>Hungary and Romania</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-05-27 10:11:14 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2010-05-27 09:31:15 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-06-11 15:23:36 +0100" MODIFIED_BY="Helen Collins">Procaine is a controversial substance that has been used for "antiageing" effects including cognitive improvement for more than 50 years</TITLE>
<SUMMARY_BODY MODIFIED="2010-05-27 09:31:15 +0100" MODIFIED_BY="[Empty name]">
<P>Preparations which contain procaine as a component are widely promoted and used in several countries.</P>
<P>In analysing the effect of procaine and its preparations from 3 studies with a total of 427 participants, there was no evidence for benefit in the prevention or treatment of dementia or cognitive impairment.</P>
<P>There were a few but some serious adverse events related to long-term use of procaine.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-05-27 09:45:13 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2008-06-11 15:23:06 +0100" MODIFIED_BY="Helen Collins">
<P>Procaine is a controversial substance which has been used for "antiageing" effects including cognitive improvement for more than 50 years.</P>
<P>Preparations which contain procaine as a component are claimed to prevent, reverse and interrupt dementia. Several products are widely promoted and can be purchased "over the counter" outside the US and via the Internet. Procaine preparations are said to be readily available in over 70 countries and to be used by more than 100 million people.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the efficacy and adverse effects of procaine (and preparations containing procaine as a component) on cognitive function in the treatment of people with dementia as well as healthy elderly people.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-04-28 12:39:50 +0100" MODIFIED_BY="[Empty name]">
<P>References regarding trials with people with dementia or cognitive impairment were identified from a search <A HREF="http://www.medicine.ox.ac.uk/alois">ALOIS</A>: the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 16 April 2010 using the search term: procaine. <I>The Cochrane Library</I>, MEDLINE, EMBASE, PsycINFO, CINAHL and LILACS were searched on 16 April 2010 to find references to ensure the search was as up-to-date and as comprehensive as possible.</P>
<P>For more details on what ALOIS contains see <A HREF="http://www.medicine.ox.ac.uk/alois/content/about-alois">About ALOIS</A>.<BR/>
</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-07-03 10:42:07 +0100" MODIFIED_BY="Helen Collins">
<P>All human, unconfounded, randomized double-blind trials in which treatment with procaine was administered for its effects on cognitive function and behavioural symptoms in demented or healthy elderly participants in parallel group comparison with placebo.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-05-26 13:17:19 +0100" MODIFIED_BY="[Empty name]">
<P>The two review authors independently selected trials, assessed quality, extracted data, and performed the data analysis.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-05-27 09:45:13 +0100" MODIFIED_BY="[Empty name]">
<P>Pooling data from two studies with a total of 415 participants showed a detrimental effect of procaine in terms of causing side effects (20/208 active versus 3/207 placebo, OR 7.30, 95% CI 2.13 to 25.02, P = 0.002). In patients with dementia, a single small study of 12 participants (all women) also suggested a detrimental effect. Two trials referring to healthy elderly persons suggested a positive effect of procaine preparation on cognitive function.  Meta-analysis of beneficial outcomes was not appropriate due to the different preparations, durations and poor quality of trials. Most trials were performed before the 1990s and none reported any criteria for cognitive decline and dementia.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-07-03 10:42:58 +0100" MODIFIED_BY="Helen Collins">
<P>This review suggests that the evidence for detrimental effects of procaine and its preparations is stronger than the evidence for benefit in preventing and/or treating dementia or cognitive impairment.</P>
<P>There is some evidence from older studies that procaine preparations might improve memory in persons without cognitive impairment. However, the clear evidence of side effects suggests that the risks might outweigh the benefits. In the light of this, the strong marketing claims for procaine preparations should be withdrawn until trials of adequate size, duration and quality have been conducted.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-05-27 10:11:14 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2010-05-27 10:11:14 +0100" MODIFIED_BY="[Empty name]">
<P>Dementia is an important public health problem. As the prevalence of dementia increases with age, and the proportion of the elderly in the world population is expected to increase over time, the impact of dementia on society will increase. More effective primary prevention might result in a decrease in the prevalence of dementia. Pharmacological and non-pharmacological treatments have been developed which aim to treat the causes of dementia as well as to interrupt the disease. Many other drugs have been claimed to provide symptomatic or disease-modifying effects.</P>
<P>Procaine hydrochloride or novocaine was first synthesized by the German chemist Alfred Einhorn in 1905 and was used as a local anaesthetic. Administered intravenously from 1925, it was described as effective in migraine, pain, and asthma. After 1950 it was also used for its "antiageing" effects. Preparations which contain procaine as a component (e.g. Gerovital, Gerovital H3, Procaine Hydrochloride, KH3, GH3, Trofibial H3, Aslavital, or Zell H3) are claimed to prevent, reverse and interrupt dementia and to have the following beneficial effects: neuron regeneration, cell membrane modulation, protection against cerebral anoxia (a condition in which there is a lack of oxygen supply of the brain), antioxidant activity, increasing resistance to infections and toxins, antidepressant activity (as a reversible inhibitor of monoaminoxidase), increasing serum HDL-C concentrations and decreasing triglyceride levels. They are also claimed to be thyroid inhibitors, muscle relaxants and antihistamines. They are said to decrease plasmacortisol levels and therefore to have an anti-stress effect, helping to prevent dementia. In the United States, the Food and Drug Administration banned Gerovital H3 from interstate commerce as an unapproved drug and, since 1982, has prohibited its importation although there are indications that it, or its compounds, may still be imported under the category of a "nutrient". Whether characterized as drug or nutrient, the FDA's 1982 automatic detention alert is still in effect and bans the import of Gerovital H3 into the US as "a new drug without an approved new drug application" (<LINK REF="REF-FDA-1982" TYPE="REFERENCE">FDA 1982</LINK>).</P>
<P>In 1977 an independent review of procaine based interventions for the elderly was carried out by Ostfeld (<LINK REF="STD-Ostfeld-1977" TYPE="STUDY">Ostfeld 1977</LINK>). He reviewed all available evidence from randomized and controlled trials and concluded that there was no convincing evidence that procaine or combined drugs containing procaine had a prophylactic or therapeutic effect in pathological ageing or in the diseases of later life, including dementia. Despite this, the drugs continue to be widely promoted and can be purchased "over the counter" outside the US and via the Internet. The following websites demonstrate the intensity of these marketing efforts:</P>
<P>
<A HREF="http://www.realgerovital.com">http://www.realgerovital.com</A>, <A HREF="http://www.cellhealthmakeover.com">http://www.cellhealthmakeover.com</A>, <A HREF="http://www.achilleshealthmart.com">http://www.achilleshealthmart.com</A>, <A HREF="http://www.whiteharvest.com/gh3-the-science/romanian-rejuvenation/">http://www.whiteharvest.com/gh3-the-science/romanian-rejuvenation/</A>, <A HREF="http://www.herbalremedies.com/procaine1.html">http://www.herbalremedies.com/procaine1.html</A>, <A HREF="http://www.ultimate9.com">http://www.ultimate9.com</A>, <A HREF="http://www.hwize.com/gerovital-gh3/gerovital-gh3.html">http://www.hwize.com/gerovital-gh3/gerovital-gh3.html</A>, <A HREF="http://www.smart-drugs.com/ias-gh3-antiaging.htm">http://www.smart-drugs.com/ias-gh3-antiaging.htm</A>, <A HREF="http://www.gh3.co.uk/">http://www.gh3.co.uk/</A>
</P>
<P>The preparations themselves vary widely in active ingredients, nutritional components and other ingredients. The following are examples of the preparations available as of April 2008:<BR/>(1) Gerovital H3, GH3® - potassium metabisulphite, benzoic acid and disodium phosphate as well as procaine. VITACEL 3 and VITACEL 3sp are very similar products. Vitacel 6 is GH3 without bisulfite.<BR/>(2) ZELL H3, VITACEL 5 - procaine plus various vitamins, minerals and enzymes<BR/>(3) KH3 - procaine, hemato porphyrine, and other ingredients<BR/>(4) Aslavital is Gerovital H3 + vitamin B6 and other ingredients<BR/>(5) VITACEL 4 ASLAVITAL is Aslavital + Bee Propolis + Royal Jelly<BR/>(6) Vitacel GH7 or GH7 - procaine hydrochloride complexed with various vitamins and other biologically active compounds.</P>
<P>A host of GH7 based treatments have entered the market:<BR/>
</P>
<UL>
<LI>VITACEL 9* - GH7 + L-Carnitine + CoQ10 + Lycopene</LI>
<LI>VITACEL 8* - GH7 + Grape Seed + Ginkgo + Milk Thistle + Artichoke extracts</LI>
<LI>VITACEL GH7* PLUS 200 mg - double dose of GH7</LI>
<LI>VITACEL 7 GOLD* - a liquid preparation of GH7</LI>
<LI>Ultimate 9 (also called Procaine Vitamin H3, Ultra GH9, Ultra-H3): in Ultimate 9, so it is claimed, all the procaine hydrochloride is complexed and protected which makes it theoretically six times more active than GH3 (<LINK REF="REF-Ultimate-9-2008" TYPE="REFERENCE">Ultimate 9 2008</LINK>).</LI>
</UL>
<P>All these products can be sold (like any other product) at whatever price the distributor wishes. Consumers are warned however that "it is worth bearing in mind that a 'cheap' version often indicates corners have been cut in the manufacturing process" (<LINK REF="REF-GH3-2008" TYPE="REFERENCE">GH3 2008</LINK>).</P>
<P>At present procaine hydrochloride and preparations containing procaine as a component have an unclassified status as treatments for promoting cognition and preventing dementia. In view of the fact that the last systematic review of preparations containing procaine was performed more than 30 years ago, and given their apparent popularity as an "antiageing" treatment - the preparations are said to be readily available in over 70 countries around the world and to be used by more than 100 million people (<LINK REF="REF-GH3-2008" TYPE="REFERENCE">GH3 2008</LINK>) - a Cochrane review testing the safety and efficacy of these preparations for promoting cognition and preventing dementia was warranted.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-07-03 10:53:32 +0100" MODIFIED_BY="Helen Collins">
<SUBSECTION>
<HEADING LEVEL="2">Primary objectives</HEADING>
<P>To assess the efficacy and adverse effects of procaine (and preparations containing procaine as a component) on cognitive function in the treatment of people with dementia as well as healthy elderly people. To assess other non-cognitive effects (e.g. antidepressive) of procaine and its preparations for people with dementia and healthy elderly.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Secondary objective</HEADING>
<P>To describe the quality and quantity of research evidence available about treatments with procaine for cognitive function.</P>
</SUBSECTION>
</OBJECTIVES>
<METHODS MODIFIED="2010-04-28 12:43:33 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-07-03 10:55:46 +0100" MODIFIED_BY="Helen Collins">
<CRIT_STUDIES MODIFIED="2008-07-03 10:53:57 +0100" MODIFIED_BY="Helen Collins">
<P>All human, unconfounded, randomized double-blind trials in which treatment with procaine was administered for its effects on cognitive function and behavioural symptoms to demented or healthy elderly participants in parallel group comparison with placebo.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>People with dementia diagnosed under accepted criteria or healthy elderly people were evaluated. Diagnostic criteria include DSM (<LINK REF="REF-APA-1987" TYPE="REFERENCE">APA 1987</LINK>; <LINK REF="REF-DSM-IV-1994" TYPE="REFERENCE">DSM IV 1994</LINK>), ICD-10 (<LINK REF="REF-WHO-1992" TYPE="REFERENCE">WHO 1992</LINK>), NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association) (<LINK REF="REF-McKhann-1984" TYPE="REFERENCE">McKhann 1984</LINK>), NINDS-AIREN (National Institute of Neurological Disorders and Stroke - Association Internationale pour la Recherche et l'Enseignement en Neurosciences) (<LINK REF="REF-Rom_x00e1_n-1993" TYPE="REFERENCE">Román 1993</LINK>) or accepted equivalents.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Preparations in which procaine is present as a component by any route of administration, at any dosage and for any duration, in comparison with placebo. </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-07-03 10:55:46 +0100" MODIFIED_BY="Helen Collins">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-07-03 10:55:46 +0100" MODIFIED_BY="Helen Collins">
<UL>
<LI>Change in cognitive function (as measured by psychometric tests)</LI>
<LI>Global impression of change</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-07-03 10:55:37 +0100" MODIFIED_BY="Helen Collins">
<UL>
<LI>Quality of life</LI>
<LI>Change in the severity of depressive signs or symptoms</LI>
<LI>Change in functional performance</LI>
<LI>Effect on carer</LI>
<LI>Death</LI>
<LI>Any adverse effects</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-04-28 12:43:33 +0100" MODIFIED_BY="[Empty name]">
<P>We searched ALOIS (<A HREF="http://www.medicine.ox.ac.uk/alois">www.medicine.ox.ac.uk/alois</A>) - the Cochrane Dementia and Cognitive Improvement Group&#8217;s Specialized Register on 16 April 2010. The search term used was: procaine</P>
<P>ALOIS is maintained by the Trials Search Co-ordinator and contains studies in the areas of dementia prevention, dementia treatment and cognitive enhancement in healthy. The studies are identified from:  </P>
<OL>
<LI>Monthly searches of a number of major healthcare databases: Medline, Embase, Cinahl, Psycinfo and Lilacs</LI>
<LI>Monthly searches of a number of trial registers: meta Register of Controlled Trials; Umin Japan Trial Register; WHO portal (which covers ClinicalTrials.gov; ISRCTN; Chinese Clinical Trials Register; German Clinical Trials Register; Iranian Registry of Clinical Trials and the Netherlands National Trials Register, plus others)</LI>
<LI>Quarterly search of <I>The Cochrane Library</I>&#8217;s Central Register of Controlled Trials (CENTRAL)</LI>
<LI>Six-monthly searches of a number of grey literature sources: ISI Web of knowledge Conference Proceedings; Index to Theses; Australasian Digital Theses</LI>
</OL>
<P>To view a list of all sources searched for ALOIS see <A HREF="http://www.medicine.ox.ac.uk/alois/content/about-alois">About ALOIS</A> on the ALOIS website.</P>
<P>Details of the search strategies used for the retrieval of reports of trials from the healthcare databases, CENTRAL and conference proceedings can be viewed in the &#8216;methods used in reviews&#8217; section within the editorial information about the <A HREF="http://mrw.interscience.wiley.com/cochrane/clabout/articles/DEMENTIA/frame.html">Dementia and Cognitive Improvement Group</A>.</P>
<P>Additional searches in each of the sources listed above to cover the timeframe from the last searches performed for the Specialized register to 16 April 2010 to ensure that the search for the review was as up-to-date as possible. The search strategies used can be seen in Appendix A.</P>
<P>Searches carried out in the previous version(s) of the review can be viewed in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-07-03 11:14:57 +0100" MODIFIED_BY="Helen Collins">
<SUBSECTION>
<HEADING LEVEL="3">Identification of studies</HEADING>
<P>The searching was performed by Vittoria Lutje and by one of the reviewers (SzSz). Screening of the results was performed independently by both reviewers (SzSz and BD) and they independently selected trials for inclusion in the review from the culled citation list. Disagreements were resolved by discussion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality assessment</HEADING>
<P>The same two reviewers (SzSz and DB) assessed the methodological quality of each trial. Methodological characteristics of each trial were entered in a table with information on the country of study, the number, age and gender of subjects randomized to the groups, the method used to diagnose dementia, inclusion and exclusion criteria, the method of randomisation, allocation concealment, method of brain imaging (none, CT, MRI, SPECT, PET) used in the study, and number of subjects lost during treatment. The methodological quality of each selected trial was assessed using the Cochrane Collaboration guidelines (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>):</P>
<P>Category A (adequate) is where the report describes allocation of treatment by:<BR/>
</P>
<UL>
<LI>Some form of centralized randomized scheme</LI>
<LI>Some form of randomization scheme controlled by a pharmacy</LI>
<LI>Numbered or coded containers</LI>
<LI>An on-site or coded computer system</LI>
<LI>Adequate use of envelopes for assignment</LI>
</UL>
<P>Category B (intermediate) is where the report describes the treatment allocation by:<BR/>
</P>
<UL>
<LI>Use of a list of table to allocate assignments</LI>
<LI>Use of envelopes or sealed envelopes not precisely explained</LI>
<LI>Use of randomization design without further detail</LI>
</UL>
<P>Category C (Inadequate) is where the report describes allocation of treatment by:<BR/>
</P>
<UL>
<LI>Alternation</LI>
<LI>Reference to case record numbers, date of birth or any other such approach</LI>
<LI>Any allocation procedure that is entirely transparent before assignment, such as an open list of random numbers or assignments</LI>
</UL>
<P>Only trials in categories A or B have been included in the review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction</HEADING>
<P>Data were extracted from the published reports. The summary statistics required for each trial and each outcome for continuous data are the mean change from baseline, the standard error of the mean change, and the number of patients for each treatment group at each assessment. Where changes from baseline are not reported, the mean, standard deviation and the number of patients for each treatment group at each time point were extracted if available.</P>
<P>For binary data the numbers in each treatment group and the numbers experiencing the outcome of interest were sought.</P>
<P>The baseline assessment is defined as the latest available assessment prior to randomization, but no longer than two months prior.</P>
<P>For each outcome measure, data were sought on every patient randomized. To allow an intention-to-treat analysis, the data were sought irrespective of compliance, whether or not the patient was subsequently deemed ineligible, or otherwise excluded from treatment or follow-up. If intention-to-treat data are not available in the publications, "on-treatment" or the data of those who completed the trial were sought and indicated as such.</P>
<P>In studies where a crossover design was used, only data from the first treatment phase after randomization were eligible for inclusion.</P>
<P>Data from titration phases prior to the randomized phase were not be used to assess safety or efficacy because patients were usually not randomized, nor were treatments concealed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data analysis</HEADING>
<P>The outcomes measured in clinical trials of dementia and cognitive impairment often arise from ordinal rating scales. Where the rating scales used in the trials have a reasonably large number of categories (more than 10), the data were treated as continuous outcomes arising from a normal distribution.</P>
<P>Summary statistics (n, mean and standard deviation) were required for each rating scale at each assessment time for each treatment group in each trial for change from baseline.</P>
<P>When change from baseline results are not reported, the required summary statistics were calculated from the baseline and assessment time treatment group means and standard deviations. In this case a zero correlation between the measurements at baseline and assessment time was assumed. This method overestimates the standard deviation of the change from baseline, but this conservative approach is considered to be preferable in a meta-analysis.</P>
<P>The meta-analysis requires the combination of data from the trials. The measure of the treatment difference for any outcome was the weighted mean difference when the pooled trials use the same rating scale or test to assess an outcome, and the standardized mean difference, which is the absolute mean difference divided by the pooled standard deviation when they used different rating scales or tests.</P>
<P>The duration of the trials may vary considerably. If the range is considered too great to combine all trials into one meta-analysis, it was divided into smaller time periods and a separate meta-analysis conducted for each period. Some trials may contribute data to more than one time period if multiple assessments have been done.</P>
<P>For binary outcomes, such as clinical improvement or no clinical improvement, the odds ratio will be used to measure treatment effect.</P>
<P>A weighted estimate of the typical treatment effect across trials was calculated.</P>
<P>An overall estimate of the treatment difference was presented. In all cases the overall estimate from a fixed-effect model was presented and a test for heterogeneity was performed. If, however, there is evidence of heterogeneity of the treatment effect between trials then either only homogeneous results were pooled, or a random-effects model was used. In this case the confidence intervals would be broader than those of a fixed-effect model.</P>
<P>The Cochrane statistical software (the latest available version of RevMan) was used for data analysis. Subgroup analysis was planned to be performed for different treatment modalities (route of administration, dosage, duration), type of dementia (Alzheimer, vascular, mixed), and regarding the components of combined drugs if possible.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-07-03 11:23:58 +0100" MODIFIED_BY="Helen Collins">
<STUDY_DESCRIPTION MODIFIED="2008-07-03 11:16:51 +0100" MODIFIED_BY="Helen Collins">
<P>Twenty-four clinical studies using procaine in different combinations were identified. Except one, all identified studies were performed before the 1990s and none report any criteria for cognitive decline and dementia. Two studies described as double-blind and placebo-controlled but without mentioning randomization were excluded.</P>
<P>In the first phase we identified eight RCTs using procaine as active treatment but only three could be included in the review (<LINK REF="STD-Cashman-1961" TYPE="STUDY">Cashman 1961</LINK>; <LINK REF="STD-Balaceanu-1989" TYPE="STUDY">Balaceanu 1989</LINK>; <LINK REF="STD-Hall-1983" TYPE="STUDY">Hall 1983</LINK>). The excluded studies were not randomized and/or included patients with diverse chronic diseases without the possibility of subgroup analysis. One RCT (<LINK REF="STD-Long-1964" TYPE="STUDY">Long 1964</LINK>) enrolled geriatric disoriented patients with a 45% loss of subjects from follow-up during the one year of study period, therefore it was excluded from analysis.</P>
<P>Two of the included studies (<LINK REF="STD-Balaceanu-1989" TYPE="STUDY">Balaceanu 1989</LINK>; <LINK REF="STD-Hall-1983" TYPE="STUDY">Hall 1983</LINK>) referred to neuropsychiatrically healthy elderly subjects, one to demented patients (<LINK REF="STD-Cashman-1961" TYPE="STUDY">Cashman 1961</LINK>).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-07-03 11:19:21 +0100" MODIFIED_BY="Helen Collins">
<P>All included studies were described as randomized but without details about the randomization process, thereby meeting grade B criteria for evidence.</P>
<P>The study of <LINK REF="STD-Balaceanu-1989" TYPE="STUDY">Balaceanu 1989</LINK> was performed in Romania and treated neurologically and mentally healthy patients hospitalized in the National Institute of Gerontology and Geriatrics. The cause of admission to the institute is not mentioned in the study nor the type or gravity of extracerebral pathology. The length of treatment with procaine (gerovital) 200 mg/day i.m. or placebo was 30 days and all participants finished the study. The side effects were reported in this study.</P>
<P>The <LINK REF="STD-Southampton-1982" TYPE="STUDY">Southampton 1982</LINK> study was published in 1983 (<LINK REF="STD-Hall-1983" TYPE="STUDY">Hall 1983</LINK>) and describes the participants as healthy elderly subjects but 4% having history of previous stroke, 16% angina pectoris or intermittent claudication and 45% electrocardiographic abnormalities. In the unpublished report of this study in the section related to withdrawals it is mentioned that "some subjects withdrew because of progressive deterioration in physical or intellectual ability, their physical frailty or mental impairment having existed before entering the trial". The authors do not describe whether these patients belonged to the active or placebo group. Treatment with procaine/haematoporphyrin (KH3) 50 mg/day per os or placebo ran for two years, the number of dropouts are given. Only side effects causing withdrawals were reported.</P>
<P>The third included study (<LINK REF="STD-Cashman-1961" TYPE="STUDY">Cashman 1961</LINK>) selected a small number of demented patients (moderate or advanced senile or arteriosclerotic dementia) for a total number of 12 injections with procaine (gerioptil) as active treatment or sterile water for the controls during one month. No criteria for dementia were mentioned in this study. All patients were re-evaluated at the end of the treatment. The presence or absence of adverse events was not mentioned.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-07-03 11:23:58 +0100" MODIFIED_BY="Helen Collins">
<P>We included two studies which enrolled "healthy elderly" persons or "mentally healthy patients" (<LINK REF="STD-Balaceanu-1989" TYPE="STUDY">Balaceanu 1989</LINK>; <LINK REF="STD-Hall-1983" TYPE="STUDY">Hall 1983</LINK>).</P>
<P>In the study of <LINK REF="STD-Balaceanu-1989" TYPE="STUDY">Balaceanu 1989</LINK>, the cognitive functions were tested by Wechsler's Memory Scale and changes from baseline could be extracted for subtests. All subjects completed the study. The changes on each subtest were dichotomized between participants who showed improvement or were unchanged and those who were worse. There are benefits associated with procaine (gerovital) after 30 days of parenteral treatment in mental control (17/41 compared with 3/40, OR 8.74, 95% CI 2.31 to 33.05, P = 0.001), digit memory (13/41 compared with 1/40, OR 18.11, 95% CI 2.24 to 146.55, P = 0.007), visual memory (9/41 compared with 1/40, OR 10.97, 95% CI 1.32 to 91.22, P = 0.03), associate learning (21/41 compared with 3/40, OR 12.95, 95% CI 3.44 to 48.79, P = 0.0002) and memory quotient (24/41 compared with 4/40, OR 12.71, 95% CI 3.81 to 42.42, P &lt; 0.0001). No significant changes were found on other subtests of Wechsler's Memory Scale such as attention, information, orientation, immediate logic recall and intelligence measured by Kohs cubes test. The number of adverse events was higher but not significantly in the procaine group than in the placebo group (7/41 versus 1/40, P = 0.06).</P>
<P>In the Southampton 1982 study published by <LINK REF="STD-Hall-1983" TYPE="STUDY">Hall 1983</LINK>, the following cognitive tests were performed: recall and recognition of familiar material, immediate free recall, delayed free recall, digit span, non-memory items of Wechsler Adult Intelligence Scale (comprehension and vocabulary) and Raven's Progressive Matrices.</P>
<P>For this study the statistical reanalysis of published and unpublished data regarding the effects of procaine on cognitive performances was not possible due to the lack of necessary information. The authors report a significant effect after two years of treatment with procaine/haematoporphyrin (KH3) 50 mg/day per os or placebo in delayed free recall favouring procaine (i.e. no change versus significant deterioration related to baseline, -0.5% versus -37.7%, P &lt; 0.01) but no other effects on cognitive items. The total withdrawals were not significantly higher in the procaine group but the difference in the number of withdrawals due to adverse events was significant between the two groups of subjects (13/167 active versus 2/167 placebo, OR 6.96, 95% CI 1.55 to 31.36, P = 0.01). The more important side effects in the active group were: migraine (4/167) and systemic lupus erythematosus syndrome (1/167) and appeared in the first year of treatment. The number of deaths during two years of treatment was similar in the two groups (18/167 active and 19/167 placebo, P = 0.86) and were described as not related to treatment.</P>
<P>The only one very small and short study (<LINK REF="STD-Cashman-1961" TYPE="STUDY">Cashman 1961</LINK>) testing the effects of procaine in dementia included a total number of 12 demented patients (six for the procaine group and six for placebo). There were no significant effects of procaine on cognitive items, moreover the result for overall changes favoured placebo (improvement of 1/6 active versus 5/6 placebo, OR 0.04, 95% CI 0.00 to 0.83, P = 0.04).</P>
<P>The meta-analysis of adverse events reported by two studies favours placebo (20/208 active versus 3/207 placebo, OR 7.30, 95% CI 2.13 to 25.02, P = 0.002)</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-07-03 11:40:37 +0100" MODIFIED_BY="Helen Collins">
<P>We analysed the effect of procaine and it's preparations on the cognitive functions of healthy or demented people.</P>
<P>Several limits and bias constrain interpretation of the results. The identified RCTs using procaine preparations for cognitive effects were performed before the 1990s and did not use acceptable criteria for cognitive impairment or dementia. They enrolled elderly patients with diverse chronic diseases; subgroup analysis was not possible, therefore, most of the trials were excluded from the analysis. The two studies enrolling "healthy" persons failed to demonstrate that all subjects were really healthy. Two included studies (<LINK REF="STD-Balaceanu-1989" TYPE="STUDY">Balaceanu 1989</LINK>; <LINK REF="STD-Cashman-1961" TYPE="STUDY">Cashman 1961</LINK>) were too short and without further follow up of the evolution of cognitive performance. The active treatment was different in each study in terms of composition and administration. We performed meta-analysis only for adverse events because the methods and/or length of treatment differed overly among the trials. Only 12 demented patients from one short study provided data for this review.</P>
<P>Both trials referring to healthy elderly persons demonstrated a positive effect of the procaine preparation: a preservation of performances on the delayed free recall item after two years (<LINK REF="STD-Hall-1983" TYPE="STUDY">Hall 1983</LINK>) and improvement of some cognitive functions, especially memory items after one month (<LINK REF="STD-Balaceanu-1989" TYPE="STUDY">Balaceanu 1989</LINK>).</P>
<P>Procaine had a negative effect on demented patients after one month of treatment as resulting from a small study (<LINK REF="STD-Cashman-1961" TYPE="STUDY">Cashman 1961</LINK>).</P>
<P>A relatively few adverse events related to procaine treatment were presented, some as transient: restlessness, dizziness, headache and others as persistent: migrainous headache, systemic lupus erythematosus.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-07-03 11:41:27 +0100" MODIFIED_BY="Helen Collins">
<IMPLICATIONS_PRACTICE MODIFIED="2008-06-11 15:28:18 +0100" MODIFIED_BY="Helen Collins">
<P>This review provides no evidence for benefit from procaine and it's preparations in preventing and treating dementia or cognitive impairment. There were a few but some serious adverse events related to longer term treatment.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-07-03 11:41:27 +0100" MODIFIED_BY="Helen Collins">
<P>There is some evidence from old studies that procaine preparations might improve memory in persons without cognitive impairment. Because there is a high interest from the general population and a strong marketing activity related to procaine preparations, longer trials on preventing cognitive decline with better methodology should be initiated.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-07-03 11:41:44 +0100" MODIFIED_BY="Helen Collins">
<P>The reviewers are grateful to Dymphna Hermans and to Jacqueline Birks for their precious help in preparing the protocol of this review and also to Helen Collins (Review Group Co-ordinator, Cochrane Dementia and Cognitive Improvement Group) for her contribution in finishing the review. We would also like to thank the consumer reviewer David Krassner.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-04-09 10:31:14 +0100" MODIFIED_BY="Helen Collins">
<P>SzSz: all correspondence, drafting of review versions, search for trials, obtaining copies of trial reports, selection of trials for inclusion/exclusion, extraction of data, entry of data, interpretation of data analyses<BR/>BD: drafting of review versions, selection of trials for inclusion/exclusion, extraction of data, entry of data, interpretation of data analyses</P>
<P>Searches: Dymphna Hermans and Vittoria Lutje<BR/>Contact editor: Gordon Wilcock<BR/>Consumer editor: David Krassner</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-07-03 12:11:16 +0100" MODIFIED_BY="Helen Collins">
<STUDIES MODIFIED="2008-04-28 09:57:16 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-04-09 10:25:01 +0100" MODIFIED_BY="Helen Collins">
<STUDY DATA_SOURCE="PUB" ID="STD-Balaceanu-1989" NAME="Balaceanu 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Balaceanu Stolnici C, Manoiu A, Vrabiescu M</AU>
<TI>Gerovital h3 effects upon human cognitive behaviour and psychomotor capacity</TI>
<SO>Romanian Journal of Gerontology and Geriatrics</SO>
<YR>1989</YR>
<VL>10</VL>
<NO>4</NO>
<PG>277-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cashman-1961" NAME="Cashman 1961" YEAR="1961">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cashman MD, Lawes TGG</AU>
<TI>A controlled trial of "Gerioptil"</TI>
<SO>BMJ</SO>
<YR>1961</YR>
<VL>1</VL>
<NO>5225</NO>
<PG>554-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Hall-1983" NAME="Hall 1983" YEAR="1983">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hall MR, Briggs RS, MacLennan WJ, Marcer D, Robinson MJ, Everett FM</AU>
<TI>The effects of procaine/haematoporphyrin on age-related decline: a double-blind trial</TI>
<SO>Age and Ageing</SO>
<YR>1983</YR>
<VL>12</VL>
<NO>4</NO>
<PG>302-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Southampton-1982" MODIFIED="2008-04-09 10:25:01 +0100" MODIFIED_BY="Helen Collins" NAME="Southampton 1982" YEAR="1982">
<REFERENCE MODIFIED="2008-04-09 10:25:01 +0100" MODIFIED_BY="Helen Collins" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>The Southampton Ageing Project</AU>
<TI>The Southampton Ageing Project: A trial of KH3</TI>
<SO>The Southampton Ageing Project</SO>
<YR>1982</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-04-28 09:57:16 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abrams-1965" NAME="Abrams 1965" YEAR="1965">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Abrams A, Tobin S, Gordon P, Pechtel C, Hilkevitch A</AU>
<TI>The effects of a European procaine preparation in an aged population</TI>
<SO>Journal of Gerontology</SO>
<YR>1965</YR>
<VL>20</VL>
<NO>2</NO>
<PG>139-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aslan-1980" NAME="Aslan 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aslan A, Vrabiescu A, Dobre M, Polovrageanu E</AU>
<TI>The aslavital treatment in the recovery of mentally-deficient children</TI>
<SO>Romanian Journal of Gerontology and Geriatrics</SO>
<YR>1980</YR>
<VL>1</VL>
<NO>1</NO>
<PG>93-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aslan A, Vrabiescu A, Dobre M</AU>
<TI>Aslavital for children in mentally deficient subjects</TI>
<SO>Romanian Journal of Gerontology and Geriatrics</SO>
<YR>1980</YR>
<VL>1</VL>
<NO>2</NO>
<PG>189-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Aslan A</AU>
<TI>A new method for prophylaxis and treatment of aging with novocain-eutrophic and rejuvenating effects</TI>
<SO>Therapiewoche</SO>
<YR>1956</YR>
<VL>7</VL>
<PG>14-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berryman-1961" NAME="Berryman 1961" YEAR="1961">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berryman JAW, Forbes HAW, Simpson-White R</AU>
<TI>Trial of procaine in old age and chronic degenerative disorders</TI>
<SO>BMJ</SO>
<YR>1961</YR>
<VL>2</VL>
<NO>5268</NO>
<PG>1683-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Czerwenka-1970" NAME="Czerwenka 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czerwenka H, Maly J, Quatember R, Tschabitscher H</AU>
<TI>Clinical and psychological investigations with a geriatric substance (in German)</TI>
<TO>Klinische und testpsychologische Untersuchungen mit einem Geriatricum</TO>
<SO>Wiener Medizinische Wochenschrift</SO>
<YR>1970</YR>
<VL>120</VL>
<NO>13</NO>
<PG>217-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fee-1961" NAME="Fee 1961" YEAR="1961">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fee SR, Clark ANG</AU>
<TI>Trial of procaine in the aged</TI>
<SO>BMJ</SO>
<YR>1961</YR>
<VL>2</VL>
<NO>5268</NO>
<PG>1680-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gericke-1961" NAME="Gericke 1961" YEAR="1961">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gericke OL, Lobbv LG, Pardoll DH</AU>
<TI>An evaluation of procaine in geriatric patients in a mental hospital</TI>
<SO>Journal of Clinical and Experimental Psychopathology</SO>
<YR>1961</YR>
<VL>22</VL>
<PG>18-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hirsch-1961" NAME="Hirsch 1961" YEAR="1961">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hirsch J</AU>
<TI>A clinical trial of procaine hydrochloride</TI>
<SO>BMJ</SO>
<YR>1961</YR>
<VL>2</VL>
<NO>5268</NO>
<PG>1684-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Isaacs-1962" NAME="Isaacs 1962" YEAR="1962">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Isaacs B</AU>
<TI>Trials of procaine in aged patients</TI>
<SO>BMJ</SO>
<YR>1962</YR>
<VL>2</VL>
<NO>5272</NO>
<PG>188-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kant-1962" NAME="Kant 1962" YEAR="1962">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kant S, Sterne DM</AU>
<TI>Evaluation of chronically ill patients treated for one year with procaine</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kent-1982" NAME="Kent 1982" YEAR="1982">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kent S</AU>
<TI>The procaine "youth" drugs</TI>
<SO>Geriatrics</SO>
<YR>1982</YR>
<VL>37</VL>
<NO>4</NO>
<PG>32-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Long-1964" NAME="Long 1964" YEAR="1964">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Long RF, Gislason SS</AU>
<TI>The effect of procaine on orientation, attention, memory and weight of aged psychiatric patients</TI>
<SO>Journal of Neuropsychiatry</SO>
<YR>1964</YR>
<VL>5</VL>
<PG>186-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-May-1962" NAME="May 1962" YEAR="1962">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>May RH, Ruland MB, Bylenga ND, Peppel HH</AU>
<TI>Prolonged procaine therapy in geriatric psychiatric patients</TI>
<SO>Geriatrics</SO>
<YR>1962</YR>
<VL>17</VL>
<PG>161-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olsen-1978" NAME="Olsen 1978" YEAR="1978">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Olsen EJ, Bank L, Jarvik LF</AU>
<TI>Gerovital-H3: a clinical trial as an antidepressant</TI>
<SO>Journal of Gerontology</SO>
<YR>1978</YR>
<VL>33</VL>
<NO>4</NO>
<PG>514-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ostfeld-1977" NAME="Ostfeld 1977" YEAR="1977">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ostfeld A, Smith CM, Stotsky BA</AU>
<TI>The systemic use of procaine in the treatment of the elderly: a review</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1977</YR>
<VL>5</VL>
<NO>1</NO>
<PG>1-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quatember-1980" NAME="Quatember 1980" YEAR="1980">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Quatember R, Maly J</AU>
<TI>Neuropsychological methods of examination of age-specific performance parameters</TI>
<TO>Neuropsychologische Untersuchungsmethoden alterssezifischer Leistungsparameter</TO>
<SO>Wiener Medizinische Wochenschrift</SO>
<YR>1980</YR>
<VL>130</VL>
<NO>21</NO>
<PG>688-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rusu-1996" NAME="Rusu 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rusu C, Borsa C, Gradinaru D, Ionescu C, Babeanu S</AU>
<TI>Antioxidant and lipid-lowering effects of the original procaine-based products</TI>
<SO>Romanian Journal of Gerontology and Geriatrics</SO>
<YR>1996</YR>
<VL>18</VL>
<NO>3-4</NO>
<PG>47-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sakalis-1974" NAME="Sakalis 1974" YEAR="1974">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sakalis G, Oh D, Gershon S, Shopsin B</AU>
<TI>A trial of gerovital H-3 in depression during senility</TI>
<SO>Current Therapeutic Research, Clinical and Experimental</SO>
<YR>1974</YR>
<VL>16</VL>
<NO>1</NO>
<PG>59-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smigel-1960" NAME="Smigel 1960" YEAR="1960">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Smigel JO, Piller J, Murphy C, Lowe C, Gibson J</AU>
<TI>H-3 (procaine hydrochloride) therapy in aging institutionalized patients: an interim report</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1960</YR>
<VL>8</VL>
<PG>785-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Valtonen-1992" MODIFIED="2008-04-28 09:57:16 +0100" MODIFIED_BY="[Empty name]" NAME="Valtonen 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-04-28 09:57:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Valtonen EJ</AU>
<TI>Procaine chloride as a universal remedy for somatic and psychic symptoms</TI>
<SO>Suomen Lookorilehti</SO>
<YR>1992</YR>
<VL>47</VL>
<NO>28</NO>
<PG>1608-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zdichynec-1977" NAME="Zdichynec 1977" YEAR="1977">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zdichynec B</AU>
<TI>Successes in novocain therapy in the control of premature ageing</TI>
<TO>Kurzmitteilung zur Novokaintherapie-Vorbeugung des vorzeitigen Alterns mittels der Novokaintherapie</TO>
<SO>Z Alternsforsch</SO>
<YR>1977</YR>
<VL>32</VL>
<NO>3</NO>
<PG>267-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zwerling-1975" NAME="Zwerling 1975" YEAR="1975">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zwerling I, Plutchik R, Hotz M, Kling R, Rubin L, Grossman J, et al</AU>
<TI>Effects of a procaine preparation (Gerovital H3) in hospitalized geriatric patients: a double-blind study</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1975</YR>
<VL>23</VL>
<NO>8</NO>
<PG>355-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-07-03 12:11:16 +0100" MODIFIED_BY="Helen Collins">
<ADDITIONAL_REFERENCES MODIFIED="2008-07-03 12:11:16 +0100" MODIFIED_BY="Helen Collins">
<REFERENCE ID="REF-APA-1987" MODIFIED="2008-07-03 12:10:26 +0100" MODIFIED_BY="Helen Collins" NAME="APA 1987" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders</SO>
<YR>1987</YR>
<EN>3rd, revised</EN>
<PB>American Psychiatric Association</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DSM-IV-1994" NAME="DSM IV 1994" TYPE="BOOK">
<AU>American Psychiartric Association.</AU>
<TI>Diagnostic and Statistical Manual of Mental Disorders</TI>
<SO>American Psychiatric Association. Vol IV</SO>
<YR>1994</YR>
<EN>IV</EN>
<PB>American Psychiatric Publishing</PB>
<CY>Washington, DC, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-1982" NAME="FDA 1982" TYPE="OTHER">
<TI>Automatic detention alert for Gerovital</TI>
<SO>http://www.fda.gov/ora/fiars/ora_import_ia6101.html</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GH3-2008" MODIFIED="2008-04-27 10:30:36 +0100" MODIFIED_BY="[Empty name]" NAME="GH3 2008" TYPE="OTHER">
<SO>http://www.gh3.co.uk/</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2008-04-09 10:22:27 +0100" MODIFIED_BY="Helen Collins" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 5.0.0 [updated February 2008]</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McKhann-1984" NAME="McKhann 1984" TYPE="JOURNAL_ARTICLE">
<AU>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM</AU>
<TI>Clinical Diagnosis of Alzheimer's Disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease</TI>
<SO>Neurology</SO>
<YR>1984</YR>
<VL>4</VL>
<PG>939-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rom_x00e1_n-1993" MODIFIED="2008-07-03 12:11:16 +0100" MODIFIED_BY="Helen Collins" NAME="Román 1993" TYPE="JOURNAL_ARTICLE">
<AU>Román CG, Tatemichi TK, Erkinjuntti T, et al</AU>
<TI>Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop</TI>
<SO>Neurology</SO>
<YR>1993</YR>
<VL>43</VL>
<PG>250-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ultimate-9-2008" MODIFIED="2008-04-27 09:37:17 +0100" MODIFIED_BY="[Empty name]" NAME="Ultimate 9 2008" TYPE="OTHER">
<TI>Development of Ultimate 9</TI>
<SO>http://www.achilleshealthmart.com/vitacel_koch.htm</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1992" NAME="WHO 1992" TYPE="BOOK">
<AU>World Health Organisation</AU>
<SO>International classification of diseases, 10th revision</SO>
<YR>1992</YR>
<PB>World Health Organisation</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-05-30 17:52:14 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-05-30 17:52:14 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-05-30 17:52:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Balaceanu-1989">
<CHAR_METHODS>
<P>Double-blind, placebo-controlled, randomized, method of randomization not detailed.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Aging persons free of neuropsychiatric pathology from the Romanian National Institute of Gerontology and Geriatrics. Procaine group: 41 patients (25 women and 16 men), mean age: 71.9 years. Placebo group: 40 patients (28 women and 12 men), mean age: 71.3 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-28 11:20:50 +0100" MODIFIED_BY="[Empty name]">
<P>Gerovital H3 or saline solution 2 x 5 ml per day i.m. during 30 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-30 17:52:14 +0100" MODIFIED_BY="[Empty name]">
<P>Psychomotor capacity, Herwig's attention test, Wechsler's Memory scale, Kohs cubes intelligence test</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No details about extracerebral diseases. Adverse effects reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cashman-1961">
<CHAR_METHODS>
<P>Double-blind, placebo-controlled, randomized, method of randomization not detailed.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Moderate or advanced senile or arterioslerotic dementia. <BR/>12 elderly women, 6 active (between 64 and 81 years old) and 6 placebo (between 76 and 84 years old)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>gerioptil or placebo, a number of 12 injections i.m. during 1 month</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Wechsler's memory test<BR/>Bender gestalt test of figure-drawing <BR/>Raven's Progressive Matrices<BR/>Mill Hill vocabulary test</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No criteria for dementia.<BR/>Adverse events not mentioned</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-03 11:44:49 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Hall-1983">
<CHAR_METHODS>
<P>Double-blind, placebo-controlled, randomized, method of randomization not detailed.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-03 11:43:51 +0100" MODIFIED_BY="Helen Collins">
<P>So-called "healthy elderly, fit enough to go through tests"<BR/>168 active and 166 placebo, all over 65 years old<BR/>Mean age of completers on entry: active: 72.8 (5.3) years (standard deviation); placebo: 73.7 (6.3)<BR/>exclusion criteria: severe diseases</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-03 11:43:58 +0100" MODIFIED_BY="Helen Collins">
<P>KH3 (procaine/haematoporphyrin) or placebo 1 x 50 mg/day per os for 2 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-03 11:44:10 +0100" MODIFIED_BY="Helen Collins">
<P>Recall and recognition of familiar material<BR/>Immediate free recall<BR/>Digit span<BR/>Wechsler Adult Intelligence Scale (comprehension, vocabulary)<BR/>Raven's Progressive Matrices</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-03 11:44:49 +0100" MODIFIED_BY="Helen Collins">
<P>There were clinical and laboratory abnormalities at screening and baseline: electrocardiographic abnormalities 45%, blood haemoglobin concentration of less than 12 g/dl in 6% and history of stroke: 4%, angina or intermittent claudication: 16%.<BR/>Dropouts: 87 subjects, 49 for active (withdrawals without side effects: 18, withdrawals for side effects: 13, death: 18), 38 for placebo (withdrawals without side-effects: 17, withdrawals for side effects: 2, death: 19)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-03 11:50:44 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Southampton-1982">
<CHAR_METHODS>
<P>Same study as Hall 1983, this is the detailed unpublished report of the trial<BR/>Double-blind, placebo-controlled, randomized, method of randomization not detailed.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-03 11:46:00 +0100" MODIFIED_BY="Helen Collins">
<P>So-called "healthy elderly, fit enough to go through tests"<BR/>168 active and 166 placebo, all over 65 years old<BR/>Mean age of completers on entry: active: 72.8 (5.3) years (standard deviation); placebo: 73.7 (6.3)<BR/>Exclusion criteria: severe diseases</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-03 11:49:12 +0100" MODIFIED_BY="Helen Collins">
<P>KH3 (procaine/haematoporphyrin) or placebo 1 x 50 mg/day for 2 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-03 11:49:19 +0100" MODIFIED_BY="Helen Collins">
<P>Recall and recognition of familiar material<BR/>Immediate free recall<BR/>Digit span<BR/>Wechsler Adult Intelligence Scale (comprehension, vocabulary)<BR/>Raven's Progressive Matrices</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-03 11:50:44 +0100" MODIFIED_BY="Helen Collins">
<P>There were clinical and laboratory abnormalities at screening and baseline: electrocardiographic abnormalities 45%, blood haemoglobin concentration of less than 12 g/dl in 6% and history of stroke: 4%, angina or intermittent claudication: 16%.<BR/>Dropouts: 87 subjects, 49 for active (withdrawals without side effects: 18, withdrawals for side effects: 13, death: 18), 38 for placebo (withdrawals without side effects: 17, withdrawals for side effects: 2, death: 19)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-07-03 12:07:10 +0100" MODIFIED_BY="Helen Collins" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-07-03 11:51:07 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Abrams-1965">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-03 11:51:07 +0100" MODIFIED_BY="Helen Collins">
<P>Randomized, double blind study comparing two procaine preparations. The study evaluates the effects of the additives and not of procaine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-03 11:51:20 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Aslan-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-03 11:51:20 +0100" MODIFIED_BY="Helen Collins">
<P>Double blind, placebo controlled study performed in children with mental deficiency.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-03 11:51:44 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Berryman-1961">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-03 11:51:44 +0100" MODIFIED_BY="Helen Collins">
<P>RCT but heterogenous groups with diverse diseases (cerebral haemorrhage, cerebral arteriosclerosis, Parkinsonism, rheumatoid arthritis, diabetes mellitus, old breast carcinoma, senile dementia), subgroup analysis not possible.<BR/>Not healthy, not only demented subjects.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-03 11:52:13 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Czerwenka-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-03 11:52:13 +0100" MODIFIED_BY="Helen Collins">
<P>Not randomized, double blind, placebo controlled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-03 11:52:16 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Fee-1961">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-03 11:52:16 +0100" MODIFIED_BY="Helen Collins">
<P>Double blind, placebo controlled trial including physically infirm residents in an elderly home.<BR/>Cognitive functions not tested.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-03 12:00:28 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Gericke-1961">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-03 12:00:28 +0100" MODIFIED_BY="Helen Collins">
<P>Not RCT, elderly hospitalized patients with a history of arteriosclerosis or degenerative arthritis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-03 12:00:32 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Hirsch-1961">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-03 12:00:32 +0100" MODIFIED_BY="Helen Collins">
<P>Randomized, double blind, placebo controlled trial but heterogeneous groups with diverse diseases (cerebral thrombosis, Parkinson's disease, pseudobulbar palsy, senile dementia, rheumatoid arthritis, congestive cardiac failure etc.).<BR/>Cognitive functions not tested.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Isaacs-1962">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT, patients with diverse diseases, cognitive functions not tested.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-03 12:00:43 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Kant-1962">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-03 12:00:43 +0100" MODIFIED_BY="Helen Collins">
<P>Randomized, double blind, placebo controlled trial but heterogeneous group with diverse, multiple diseases (arteriosclerotic heart disease, peripheral arteriosclerosis obliterans, residuals of cerebrovascular accidents, peptic ulcer, osteoarthritis, emphysema, visual and auditory impairment, intellectual deterioration). Subgroup analysis was not possible.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kent-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review of procaine studies</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-03 12:01:00 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Long-1964">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-03 12:01:00 +0100" MODIFIED_BY="Helen Collins">
<P>Randomized, double blind, placebo controlled trial, including heterogeneous groups of disoriented psychiatric patients. No criteria for cognitive impairment or dementia. There was a 45% loss of patients from follow up during the study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-03 12:01:11 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-May-1962">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-03 12:01:11 +0100" MODIFIED_BY="Helen Collins">
<P>Not randomized, double blind, placebo controlled study on white, female, geriatric, psychiatric patients. Evaluation of cognitive functions not detailed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Olsen-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT, but patient population is of depression, no cognitive tests.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ostfeld-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review of procaine studies</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-03 12:01:25 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Quatember-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-03 12:01:25 +0100" MODIFIED_BY="Helen Collins">
<P>Not randomized, double blind, placebo controlled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-03 12:01:29 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Rusu-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-03 12:01:29 +0100" MODIFIED_BY="Helen Collins">
<P>Not randomized, not double blind, controlled study for lipid-lowering effects</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-03 12:01:34 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Sakalis-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-03 12:01:34 +0100" MODIFIED_BY="Helen Collins">
<P>Open study for depression in elderly</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-03 12:01:40 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Smigel-1960">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-03 12:01:40 +0100" MODIFIED_BY="Helen Collins">
<P>Double blind, placebo controlled study, randomization by alternation (category C, inadequate), heterogeneous group of geriatric patients with "arthritis, nervous disorders and senile mental disturbances"</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-28 10:01:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Valtonen-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-28 10:01:43 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, healthy volunteers, subjective assessment of 36 symptoms, cognitive functions not tested.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-03 12:01:56 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Zdichynec-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-03 12:01:56 +0100" MODIFIED_BY="Helen Collins">
<P>Not randomized, double blind, placebo controlled study on arteriosclerotic cardiovascular and cerebrovascular patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-03 12:07:10 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Zwerling-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-03 12:07:10 +0100" MODIFIED_BY="Helen Collins">
<P>Not randomized, double blind, placebo controlled, small study in hospitalized geriatric patients with organic brain dysfunction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-07-03 11:50:58 +0100" MODIFIED_BY="Helen Collins">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2008-07-03 11:50:48 +0100" MODIFIED_BY="Helen Collins" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 11:43:01 +0100" MODIFIED_BY="Helen Collins" RESULT="UNKNOWN" STUDY_ID="STD-Balaceanu-1989">
<DESCRIPTION>
<P>Not detailed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 11:43:28 +0100" MODIFIED_BY="Helen Collins" RESULT="UNKNOWN" STUDY_ID="STD-Cashman-1961">
<DESCRIPTION>
<P>Not detailed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 11:45:07 +0100" MODIFIED_BY="Helen Collins" RESULT="UNKNOWN" STUDY_ID="STD-Hall-1983">
<DESCRIPTION>
<P>Insufficiently detailed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 11:50:48 +0100" MODIFIED_BY="Helen Collins" RESULT="UNKNOWN" STUDY_ID="STD-Southampton-1982">
<DESCRIPTION>
<P>Insufficiently detailed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-07-03 11:50:52 +0100" MODIFIED_BY="Helen Collins" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 11:42:53 +0100" MODIFIED_BY="Helen Collins" RESULT="UNKNOWN" STUDY_ID="STD-Balaceanu-1989">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 11:43:26 +0100" MODIFIED_BY="Helen Collins" RESULT="UNKNOWN" STUDY_ID="STD-Cashman-1961">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 11:45:12 +0100" MODIFIED_BY="Helen Collins" RESULT="UNKNOWN" STUDY_ID="STD-Hall-1983">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 11:50:52 +0100" MODIFIED_BY="Helen Collins" RESULT="UNKNOWN" STUDY_ID="STD-Southampton-1982">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2008-07-03 11:50:55 +0100" MODIFIED_BY="Helen Collins" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1" REF_IDS="CMP-001.01 CMP-001.02 CMP-001.03 CMP-001.04 CMP-003.05 CMP-003.04 CMP-003.03 CMP-003.02 CMP-003.01 CMP-002.03 CMP-002.02 CMP-002.01 CMP-001.11 CMP-001.10 CMP-001.09 CMP-001.08 CMP-001.07 CMP-001.06 CMP-001.05 CMP-004.01">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-03 11:42:59 +0100" MODIFIED_BY="Helen Collins" RESULT="UNKNOWN" STUDY_ID="STD-Balaceanu-1989">
<DESCRIPTION>
<P>Not detailed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-03 11:43:33 +0100" MODIFIED_BY="Helen Collins" RESULT="UNKNOWN" STUDY_ID="STD-Cashman-1961">
<DESCRIPTION>
<P>Not sufficiently detailed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-03 11:45:14 +0100" MODIFIED_BY="Helen Collins" RESULT="UNKNOWN" STUDY_ID="STD-Hall-1983">
<DESCRIPTION>
<P>Insufficiently detailed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-03 11:50:55 +0100" MODIFIED_BY="Helen Collins" RESULT="UNKNOWN" STUDY_ID="STD-Southampton-1982">
<DESCRIPTION>
<P>Insufficiently detailed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2008-04-28 09:28:53 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1" REF_IDS="CMP-001.01 CMP-001.02 CMP-001.03 CMP-001.04 CMP-001.05 CMP-001.06 CMP-001.07 CMP-001.08 CMP-001.09 CMP-001.10 CMP-001.11 CMP-002.01 CMP-002.02 CMP-002.03 CMP-003.01 CMP-003.02 CMP-003.03 CMP-003.04 CMP-003.05 CMP-004.01">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-04-27 22:35:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Balaceanu-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-04-28 09:09:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cashman-1961">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-04-28 09:28:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hall-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-04-28 09:28:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Southampton-1982">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2008-07-03 11:50:58 +0100" MODIFIED_BY="Helen Collins" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-04-27 22:35:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Balaceanu-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-04-28 09:14:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cashman-1961">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 11:45:17 +0100" MODIFIED_BY="Helen Collins" RESULT="UNKNOWN" STUDY_ID="STD-Hall-1983">
<DESCRIPTION>
<P>Only side effects causing withdrawals were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 11:50:58 +0100" MODIFIED_BY="Helen Collins" RESULT="UNKNOWN" STUDY_ID="STD-Southampton-1982">
<DESCRIPTION>
<P>Only side effects causing withdrawals were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2008-07-03 11:43:38 +0100" MODIFIED_BY="Helen Collins" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 11:43:04 +0100" MODIFIED_BY="Helen Collins" RESULT="UNKNOWN" STUDY_ID="STD-Balaceanu-1989">
<DESCRIPTION>
<P>The study was too short, no data about follow up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-03 11:43:38 +0100" MODIFIED_BY="Helen Collins" RESULT="UNKNOWN" STUDY_ID="STD-Cashman-1961">
<DESCRIPTION>
<P>Short study with small number of patients, no follow up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-04-28 09:28:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hall-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-04-28 09:28:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Southampton-1982">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2010-05-26 19:56:59 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2010-05-26 19:56:59 +0100" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2010-05-26 19:56:59 +0100" MODIFIED_BY="Grade Profiler">procaine compared to placebo for cognitive enhancement and dementia</TITLE>
<TABLE COLS="7" ROWS="7">
<TR>
<TD COLSPAN="7">
<P>
<B>procaine compared to placebo for cognitive enhancement and dementia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> "healthy" old persons and demented women<BR/>
<B>Settings:</B> <BR/>
<B>Intervention:</B> procaine <SUP>1</SUP>
<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>procaine </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>cognitive function improvement in "healthy" elderly persons</B>
<BR/>Wechsler's memory scale<SUP>2</SUP>
<BR/>Follow-up: 30 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>OR 12.71 </B>
<BR/>(3.81 to 42.42)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>81<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>585 per 1000</B>
<BR/>(297 to 825)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>cognitive function improvement in demented women</B>
<BR/>Wechsler's memory scale<SUP>2</SUP>
<BR/>Follow-up: 30 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>OR 0.04 </B>
<BR/>(0 to 1.12)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>12<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>3,5,6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>667 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>74 per 1000</B>
<BR/>(0 to 692)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>overall changes from baseline in "healthy persons</B>
<SUP>7</SUP> - not measured</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable<SUP>7</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>overall changes from baseline in demented women</B>
<BR/>Follow-up: 30 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>OR 0.04 </B>
<BR/>(0 to 0.83)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>12<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>3,5,6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>833 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>166 per 1000</B>
<BR/>(0 to 805)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>total adverse events in "healthy" persons</B>
<BR/>Follow-up: 30 days to 2 years </P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low risk population<SUP>8</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>OR 7.3 </B>
<BR/>(2.13 to 25.02)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>415<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,4,9</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>10 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>69 per 1000</B>
<BR/>(21 to 202)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High risk population<SUP>8</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>20 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>130 per 1000</B>
<BR/>(42 to 338)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> procaine was used for 30 days in two studies and for 2 years in one other study<BR/>
<SUP>2</SUP> memory quotient rated as improved - not improved related to the baseline<BR/>
<SUP>3</SUP> randomisation not detailed<BR/>
<SUP>4</SUP> not really "healthy" subjects<BR/>
<SUP>5</SUP> short trial without follow up<BR/>
<SUP>6</SUP> small number of patients<BR/>
<SUP>7</SUP> no data about overall changes<BR/>
<SUP>8</SUP> different length of two trials and different way of administration: i.m. and per os<BR/>
<SUP>9</SUP> one trial was very short without follow up and one trial reported only side effects causing withdrawals </P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2010-06-10 13:53:52 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-07-03 12:16:53 +0100" MODIFIED_BY="Helen Collins">
<COMPARISON ID="CMP-001" MODIFIED="2008-07-03 12:14:40 +0100" MODIFIED_BY="Helen Collins" NO="1">
<NAME>Procaine 200 mg/day i.m. during 30 days vs placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.9497156355203926" CI_START="0.6416610824557522" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.5919732441471572" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.5965658292036942" LOG_CI_START="-0.1926943004115671" LOG_EFFECT_SIZE="0.2019357643960635" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.31589404556643397" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="1.002931253095943">
<NAME>attention, Herwig's test (change from baseline)</NAME>
<GROUP_LABEL_1>procaine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours procaine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.9497156355203926" CI_START="0.6416610824557522" DF="0" EFFECT_SIZE="1.5919732441471572" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="23" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.5965658292036942" LOG_CI_START="-0.1926943004115671" LOG_EFFECT_SIZE="0.2019357643960635" NO="1" P_CHI2="1.0" P_Z="0.31589404556643397" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="1.002931253095943">
<NAME>procaine 10 ml/day after 30 days</NAME>
<DICH_DATA CI_END="3.9497156355203926" CI_START="0.6416610824557522" EFFECT_SIZE="1.5919732441471572" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="23" LOG_CI_END="0.5965658292036942" LOG_CI_START="-0.1926943004115671" LOG_EFFECT_SIZE="0.2019357643960635" ORDER="1388" O_E="0.0" SE="0.46361530703665577" STUDY_ID="STD-Balaceanu-1989" TOTAL_1="41" TOTAL_2="40" VAR="0.2149391529186926" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="110.1973664727548" CI_START="0.2384979487194325" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="5.1265822784810124" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="2.042171215749732" LOG_CI_START="-0.6225153519012776" LOG_EFFECT_SIZE="0.7098279319242271" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.29639138054114644" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="1.044203246026377">
<NAME>information, Wechsler's Memory Scale (change from baseline)</NAME>
<GROUP_LABEL_1>procaine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours procaine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="110.1973664727548" CI_START="0.2384979487194325" DF="0" EFFECT_SIZE="5.1265822784810124" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="2.042171215749732" LOG_CI_START="-0.6225153519012776" LOG_EFFECT_SIZE="0.7098279319242271" NO="1" P_CHI2="1.0" P_Z="0.29639138054114644" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="1.044203246026377">
<NAME>procaine 10 ml/day after 30 days</NAME>
<DICH_DATA CI_END="110.1973664727548" CI_START="0.2384979487194325" EFFECT_SIZE="5.1265822784810124" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.042171215749732" LOG_CI_START="-0.6225153519012776" LOG_EFFECT_SIZE="0.7098279319242271" ORDER="1389" O_E="0.0" SE="1.5652500802494451" STUDY_ID="STD-Balaceanu-1989" TOTAL_1="41" TOTAL_2="40" VAR="2.450007813720894" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="75.84709348097547" CI_START="0.11865978756664478" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="1.879938942942664" LOG_CI_START="-0.9256964335033394" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.5050175602147271" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="0.6666158285284205">
<NAME>orientation, Wechsler's Memory Scale (change from baseline)</NAME>
<GROUP_LABEL_1>procaine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours procaine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="75.84709348097547" CI_START="0.11865978756664478" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="1.879938942942664" LOG_CI_START="-0.9256964335033394" LOG_EFFECT_SIZE="0.47712125471966244" NO="1" P_CHI2="1.0" P_Z="0.5050175602147271" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="0.6666158285284205">
<NAME>procaine 10 ml/day after 30 days</NAME>
<DICH_DATA CI_END="75.84709348097547" CI_START="0.11865978756664478" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.879938942942664" LOG_CI_START="-0.9256964335033394" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1390" O_E="0.0" SE="1.6480441082434807" STUDY_ID="STD-Balaceanu-1989" TOTAL_1="41" TOTAL_2="40" VAR="2.7160493827160495" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="33.049478691727806" CI_START="2.3092538934594935" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="8.73611111111111" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="1.5191646135011885" LOG_CI_START="0.36347168452681244" LOG_EFFECT_SIZE="0.9413181490140005" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.0014089925088699633" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="3.192802558199705">
<NAME>mental control, Wechsler's Memory Scale (change from baseline)</NAME>
<GROUP_LABEL_1>procaine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours procaine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="33.049478691727806" CI_START="2.3092538934594935" DF="0" EFFECT_SIZE="8.73611111111111" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="3" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="1.5191646135011885" LOG_CI_START="0.36347168452681244" LOG_EFFECT_SIZE="0.9413181490140005" NO="1" P_CHI2="1.0" P_Z="0.0014089925088699633" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="3.192802558199705">
<NAME>procaine 10 ml/day after 30 days</NAME>
<DICH_DATA CI_END="33.049478691727806" CI_START="2.3092538934594935" EFFECT_SIZE="8.73611111111111" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="3" LOG_CI_END="1.5191646135011885" LOG_CI_START="0.36347168452681244" LOG_EFFECT_SIZE="0.9413181490140005" ORDER="1391" O_E="0.0" SE="0.6788597472518103" STUDY_ID="STD-Balaceanu-1989" TOTAL_1="41" TOTAL_2="40" VAR="0.46085055643879175" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.930002171516408" CI_START="0.9752683513187872" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.4048582995951415" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.7730548523992408" LOG_CI_START="-0.010875868956185251" LOG_EFFECT_SIZE="0.3810894917215278" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.05670461079346921" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="1.905580833391585">
<NAME>immediate logic recall, Wechsler's Memory Scale (change from baseline)</NAME>
<GROUP_LABEL_1>procaine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours procaine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.930002171516408" CI_START="0.9752683513187872" DF="0" EFFECT_SIZE="2.4048582995951415" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="13" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.7730548523992408" LOG_CI_START="-0.010875868956185251" LOG_EFFECT_SIZE="0.3810894917215278" NO="1" P_CHI2="1.0" P_Z="0.05670461079346921" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="1.905580833391585">
<NAME>procaine 10 ml/day after 30 days</NAME>
<DICH_DATA CI_END="5.930002171516408" CI_START="0.9752683513187872" EFFECT_SIZE="2.4048582995951415" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="13" LOG_CI_END="0.7730548523992408" LOG_CI_START="-0.010875868956185251" LOG_EFFECT_SIZE="0.3810894917215278" ORDER="1392" O_E="0.0" SE="0.4604847862438322" STUDY_ID="STD-Balaceanu-1989" TOTAL_1="41" TOTAL_2="40" VAR="0.21204623836202785" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="146.55409661358183" CI_START="2.237184971454387" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="18.107142857142858" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="2.1659979627390182" LOG_CI_START="0.3497018932432154" LOG_EFFECT_SIZE="1.2578499279911168" METHOD="MH" MODIFIED="2008-07-03 12:12:53 +0100" MODIFIED_BY="Helen Collins" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.006633779783672056" Q="0.0" RANDOM="NO" SCALE="161.49528230241512" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="41" TOTAL_2="40" WEIGHT="99.99999999999999" Z="2.7146901853983083">
<NAME>digit memory, Wechsler's Memory Scale (change from baseline)</NAME>
<GROUP_LABEL_1>procaine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours procaine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="146.55409661358183" CI_START="2.237184971454387" DF="0" EFFECT_SIZE="18.107142857142858" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="1" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="2.1659979627390182" LOG_CI_START="0.3497018932432154" LOG_EFFECT_SIZE="1.2578499279911168" NO="1" P_CHI2="1.0" P_Z="0.006633779783672056" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="99.99999999999999" Z="2.7146901853983083">
<NAME>procaine 10 ml/day after 30 days</NAME>
<DICH_DATA CI_END="146.55409661358183" CI_START="2.237184971454387" EFFECT_SIZE="18.107142857142858" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="1" LOG_CI_END="2.1659979627390182" LOG_CI_START="0.3497018932432154" LOG_EFFECT_SIZE="1.2578499279911168" ORDER="1393" O_E="0.0" SE="1.0669013020323803" STUDY_ID="STD-Balaceanu-1989" TOTAL_1="41" TOTAL_2="40" VAR="1.1382783882783882" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="91.21913504311581" CI_START="1.3189499824311248" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="10.96875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="1.9600859498630114" LOG_CI_START="0.12022832642882479" LOG_EFFECT_SIZE="1.040157138145918" METHOD="MH" MODIFIED="2008-07-03 12:13:11 +0100" MODIFIED_BY="Helen Collins" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.026683441845068514" Q="0.0" RANDOM="NO" SCALE="92.17494088964807" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="2.2161177072201625">
<NAME>visual memory, Wechsler's Memory Scale (change from baseline)</NAME>
<GROUP_LABEL_1>procaine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours procaine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="91.21913504311581" CI_START="1.3189499824311248" DF="0" EFFECT_SIZE="10.96875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="1.9600859498630114" LOG_CI_START="0.12022832642882479" LOG_EFFECT_SIZE="1.040157138145918" NO="1" P_CHI2="1.0" P_Z="0.026683441845068514" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="2.2161177072201625">
<NAME>procaine 10 ml/day after 30 days</NAME>
<DICH_DATA CI_END="91.21913504311581" CI_START="1.3189499824311248" EFFECT_SIZE="10.96875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="1.9600859498630114" LOG_CI_START="0.12022832642882479" LOG_EFFECT_SIZE="1.040157138145918" ORDER="1394" O_E="0.0" SE="1.08074147544736" STUDY_ID="STD-Balaceanu-1989" TOTAL_1="41" TOTAL_2="40" VAR="1.1680021367521367" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="48.78804298550773" CI_START="3.4373688661751647" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="12.95" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="1.6883133977875886" LOG_CI_START="0.5362261390469525" LOG_EFFECT_SIZE="1.1122697684172707" METHOD="MH" MODIFIED="2008-07-03 12:13:45 +0100" MODIFIED_BY="Helen Collins" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="1.5404847060753227E-4" Q="0.0" RANDOM="NO" SCALE="53.792869566343235" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="3.7844506492911956">
<NAME>associate learning, Wechsler's Memory Scale (change from baseline)</NAME>
<GROUP_LABEL_1>procaine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours procaine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="48.78804298550773" CI_START="3.4373688661751647" DF="0" EFFECT_SIZE="12.95" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="3" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="1.6883133977875886" LOG_CI_START="0.5362261390469525" LOG_EFFECT_SIZE="1.1122697684172707" NO="1" P_CHI2="1.0" P_Z="1.5404847060753227E-4" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="3.7844506492911956">
<NAME>procaine 10 ml/day after 30 days</NAME>
<DICH_DATA CI_END="48.78804298550773" CI_START="3.437368866175165" EFFECT_SIZE="12.95" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="3" LOG_CI_END="1.6883133977875886" LOG_CI_START="0.5362261390469525" LOG_EFFECT_SIZE="1.1122697684172707" ORDER="1395" O_E="0.0" SE="0.6767417587081559" STUDY_ID="STD-Balaceanu-1989" TOTAL_1="41" TOTAL_2="40" VAR="0.45797940797940795" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="42.415395153649534" CI_START="3.8061521242928062" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="12.705882352941176" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="1.6275235173650338" LOG_CI_START="0.58048614218028" LOG_EFFECT_SIZE="1.104004829772657" METHOD="MH" MODIFIED="2008-07-03 12:14:05 +0100" MODIFIED_BY="Helen Collins" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="3.5774042238645795E-5" Q="0.0" RANDOM="NO" SCALE="41.774356813851" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="4.133204327554914">
<NAME>memory quotient, Wechsler's Memory Scale (change from baseline)</NAME>
<GROUP_LABEL_1>procaine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours procaine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="42.415395153649534" CI_START="3.8061521242928062" DF="0" EFFECT_SIZE="12.705882352941176" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="4" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="1.6275235173650338" LOG_CI_START="0.58048614218028" LOG_EFFECT_SIZE="1.104004829772657" NO="1" P_CHI2="1.0" P_Z="3.5774042238645795E-5" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="4.133204327554914">
<NAME>procaine 10 ml/day after 30 days</NAME>
<DICH_DATA CI_END="42.41539515364951" CI_START="3.806152124292807" EFFECT_SIZE="12.705882352941176" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="4" LOG_CI_END="1.6275235173650335" LOG_CI_START="0.5804861421802803" LOG_EFFECT_SIZE="1.104004829772657" ORDER="1396" O_E="0.0" SE="0.6150349371021203" STUDY_ID="STD-Balaceanu-1989" TOTAL_1="41" TOTAL_2="40" VAR="0.37826797385620914" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.071238450646724" CI_START="0.3067301799028271" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9705882352941176" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.4873135363323121" LOG_CI_START="-0.5132434906610474" LOG_EFFECT_SIZE="-0.012964977164367647" METHOD="MH" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="0.9594900837758702" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="0.05079348326382496">
<NAME>intelligence - Kohs cubes test (change from baseline)</NAME>
<GROUP_LABEL_1>procaine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours procaine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.071238450646724" CI_START="0.3067301799028271" DF="0" EFFECT_SIZE="0.9705882352941176" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="0.4873135363323121" LOG_CI_START="-0.5132434906610474" LOG_EFFECT_SIZE="-0.012964977164367647" NO="1" P_CHI2="1.0" P_Z="0.9594900837758702" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="0.05079348326382496">
<NAME>procaine 10 ml/day after 30 days</NAME>
<DICH_DATA CI_END="3.0712384506467236" CI_START="0.30673017990282714" EFFECT_SIZE="0.9705882352941176" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.487313536332312" LOG_CI_START="-0.5132434906610472" LOG_EFFECT_SIZE="-0.012964977164367647" ORDER="1397" O_E="0.0" SE="0.5877321504930612" STUDY_ID="STD-Balaceanu-1989" TOTAL_1="41" TOTAL_2="40" VAR="0.34542908072319833" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="68.59870524196872" CI_START="0.9398348417770652" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="8.029411764705882" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="1.8363159187450178" LOG_CI_START="-0.02694845874801617" LOG_EFFECT_SIZE="0.9046837299985009" METHOD="MH" MODIFIED="2008-07-03 12:14:40 +0100" MODIFIED_BY="Helen Collins" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.05700533276874918" Q="0.0" RANDOM="NO" SCALE="89.21831999979418" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="1.9032699273542026">
<NAME>number of patients with at least one adverse event during procaine 10 ml/day after 30 days</NAME>
<GROUP_LABEL_1>procaine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours procaine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="68.59870524196872" CI_START="0.9398348417770652" DF="0" EFFECT_SIZE="8.029411764705882" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="1.8363159187450178" LOG_CI_START="-0.02694845874801617" LOG_EFFECT_SIZE="0.9046837299985009" NO="1" P_CHI2="1.0" P_Z="0.05700533276874918" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="1.9032699273542026">
<NAME>number of patients with at least one adverse event during procaine 10 ml/day after 30 days</NAME>
<DICH_DATA CI_END="68.59870524196872" CI_START="0.9398348417770652" EFFECT_SIZE="8.029411764705882" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.8363159187450178" LOG_CI_START="-0.02694845874801617" LOG_EFFECT_SIZE="0.9046837299985009" ORDER="1398" O_E="0.0" SE="1.0944907186468285" STUDY_ID="STD-Balaceanu-1989" TOTAL_1="41" TOTAL_2="40" VAR="1.1979099332040508" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-07-03 12:15:16 +0100" MODIFIED_BY="Helen Collins" NO="2">
<NAME>Procaine/hematoporphyrin (KH3) 50 mg/day per os during 2 years vs placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.289685056837615" CI_START="0.9583132165199125" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.7755417956656347" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.5171543220762175" LOG_CI_START="-0.018492522263850314" LOG_EFFECT_SIZE="0.24933089990618362" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.06805635690099633" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="167" TOTAL_2="167" WEIGHT="100.0" Z="1.824633484590573">
<NAME>withdrawals during the treatment with procaine/hematoporphyrin 50 mg/day 2 years</NAME>
<GROUP_LABEL_1>procaine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours procaine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.289685056837615" CI_START="0.9583132165199125" DF="0" EFFECT_SIZE="1.7755417956656347" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="19" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.5171543220762175" LOG_CI_START="-0.018492522263850314" LOG_EFFECT_SIZE="0.24933089990618362" NO="1" P_CHI2="1.0" P_Z="0.06805635690099633" STUDIES="1" TAU2="0.0" TOTAL_1="167" TOTAL_2="167" WEIGHT="100.0" Z="1.824633484590573">
<NAME>procaine/hematoporphyrin 50 mg/day 2 years</NAME>
<DICH_DATA CI_END="3.289685056837615" CI_START="0.9583132165199125" EFFECT_SIZE="1.7755417956656347" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="19" LOG_CI_END="0.5171543220762175" LOG_CI_START="-0.018492522263850314" LOG_EFFECT_SIZE="0.24933089990618362" ORDER="1399" O_E="0.0" SE="0.31464160785999806" STUDY_ID="STD-Hall-1983" TOTAL_1="167" TOTAL_2="167" VAR="0.0989993413967248" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="31.362245187189615" CI_START="1.5464860765139086" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="6.964285714285714" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="1.4964071457695531" LOG_CI_START="0.18934601427104433" LOG_EFFECT_SIZE="0.8428765800202989" METHOD="MH" MODIFIED="2008-07-03 12:14:56 +0100" MODIFIED_BY="Helen Collins" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.011477312530503724" Q="0.0" RANDOM="NO" SCALE="43.15857937591307" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="167" TOTAL_2="167" WEIGHT="100.0" Z="2.5278201614917553">
<NAME>withdrawals due to adverse event during the treatment with procaine (KH3) 50 mg/day 2 years</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours procaine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="31.362245187189615" CI_START="1.5464860765139086" DF="0" EFFECT_SIZE="6.964285714285714" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="2" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="1.4964071457695531" LOG_CI_START="0.18934601427104433" LOG_EFFECT_SIZE="0.8428765800202989" NO="1" P_CHI2="1.0" P_Z="0.011477312530503724" STUDIES="1" TAU2="0.0" TOTAL_1="167" TOTAL_2="167" WEIGHT="100.0" Z="2.5278201614917553">
<NAME>withdrawals due to adverse event during the treatment with procaine (KH3) 50 mg/day 2 years</NAME>
<DICH_DATA CI_END="31.36224518718963" CI_START="1.5464860765139083" EFFECT_SIZE="6.964285714285714" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="2" LOG_CI_END="1.4964071457695534" LOG_CI_START="0.18934601427104428" LOG_EFFECT_SIZE="0.8428765800202989" ORDER="1400" O_E="0.0" SE="0.767774178699173" STUDY_ID="STD-Hall-1983" TOTAL_1="167" TOTAL_2="167" VAR="0.5894771894771895" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.86417190393212" CI_START="0.4750099907295264" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9410102437301306" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.2704859581718255" LOG_CI_START="-0.3232972559055047" LOG_EFFECT_SIZE="-0.026405648866839566" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.861614046204048" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="167" TOTAL_2="167" WEIGHT="100.0" Z="0.17431991858455045">
<NAME>death during the treatment with procaine/hematoporphyrin 50 mg/day 2 years</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours procaine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.86417190393212" CI_START="0.4750099907295264" DF="0" EFFECT_SIZE="0.9410102437301306" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.2704859581718255" LOG_CI_START="-0.3232972559055047" LOG_EFFECT_SIZE="-0.026405648866839566" NO="1" P_CHI2="1.0" P_Z="0.861614046204048" STUDIES="1" TAU2="0.0" TOTAL_1="167" TOTAL_2="167" WEIGHT="100.0" Z="0.17431991858455045">
<NAME>death during the treatment with procaine/hematoporphyrin 50 mg/day 2 years</NAME>
<DICH_DATA CI_END="1.86417190393212" CI_START="0.4750099907295264" EFFECT_SIZE="0.9410102437301306" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="0.2704859581718255" LOG_CI_START="-0.3232972559055047" LOG_EFFECT_SIZE="-0.026405648866839566" ORDER="1401" O_E="0.0" SE="0.34879119922333746" STUDY_ID="STD-Hall-1983" TOTAL_1="167" TOTAL_2="167" VAR="0.12165530065565387" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2008-07-03 12:16:34 +0100" MODIFIED_BY="Helen Collins" NO="3">
<NAME>Procaine (gerioptil H3) 12 injections/1 month i.m. vs placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1194811892714502" CI_START="0.0016313662927685824" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.042735042735042736" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.04901680049276694" LOG_CI_START="-2.7874485153130526" LOG_EFFECT_SIZE="-1.369215857410143" METHOD="MH" MODIFIED="2008-07-03 12:15:55 +0100" MODIFIED_BY="Helen Collins" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.058461151856994735" Q="0.0" RANDOM="NO" SCALE="526.138489367243" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0" Z="1.8922239257648845">
<NAME>memory quotient, Wechsler's Memory Scale (change from baseline)</NAME>
<GROUP_LABEL_1>procaine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours procaine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1194811892714502" CI_START="0.0016313662927685824" DF="0" EFFECT_SIZE="0.042735042735042736" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.04901680049276694" LOG_CI_START="-2.7874485153130526" LOG_EFFECT_SIZE="-1.369215857410143" NO="1" P_CHI2="1.0" P_Z="0.058461151856994735" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0" Z="1.8922239257648845">
<NAME>gerioptil H3 12 injections/1 month</NAME>
<DICH_DATA CI_END="1.1194811892714507" CI_START="0.0016313662927685808" EFFECT_SIZE="0.042735042735042736" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.04901680049276711" LOG_CI_START="-2.787448515313053" LOG_EFFECT_SIZE="-1.369215857410143" ORDER="1402" O_E="0.0" SE="1.6661537672340978" STUDY_ID="STD-Cashman-1961" TOTAL_1="6" TOTAL_2="6" VAR="2.776068376068376" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.153502458036732" CI_START="0.048510697731429714" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.7121024875250384" LOG_CI_START="-1.3141624788530009" LOG_EFFECT_SIZE="-0.3010299956639812" METHOD="MH" MODIFIED="2008-07-03 12:16:07 +0100" MODIFIED_BY="Helen Collins" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.5603241438828968" Q="0.0" RANDOM="NO" SCALE="53.792869566343235" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0" Z="0.582360115342955">
<NAME>figure-drawing, Bender gestalt test (change from baseline)</NAME>
<GROUP_LABEL_1>procaine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours procaine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.153502458036732" CI_START="0.048510697731429714" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.7121024875250384" LOG_CI_START="-1.3141624788530009" LOG_EFFECT_SIZE="-0.3010299956639812" NO="1" P_CHI2="1.0" P_Z="0.5603241438828968" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0" Z="0.582360115342955">
<NAME>gerioptil H3 12 injections/1 month</NAME>
<DICH_DATA CI_END="5.153502458036732" CI_START="0.048510697731429714" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.7121024875250384" LOG_CI_START="-1.3141624788530009" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="1403" O_E="0.0" SE="1.1902380714238083" STUDY_ID="STD-Cashman-1961" TOTAL_1="6" TOTAL_2="6" VAR="1.4166666666666665" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.153502458036732" CI_START="0.048510697731429714" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.7121024875250384" LOG_CI_START="-1.3141624788530009" LOG_EFFECT_SIZE="-0.3010299956639812" METHOD="MH" MODIFIED="2008-07-03 12:16:15 +0100" MODIFIED_BY="Helen Collins" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.5603241438828968" Q="0.0" RANDOM="NO" SCALE="30.673379120173312" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0" Z="0.582360115342955">
<NAME>intellectual capacity, Raven's Progressive Matrices (change from baseline)</NAME>
<GROUP_LABEL_1>procaine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours procaine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.153502458036732" CI_START="0.048510697731429714" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.7121024875250384" LOG_CI_START="-1.3141624788530009" LOG_EFFECT_SIZE="-0.3010299956639812" NO="1" P_CHI2="1.0" P_Z="0.5603241438828968" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0" Z="0.582360115342955">
<NAME>gerioptil H3 12 injections/1 month</NAME>
<DICH_DATA CI_END="5.153502458036732" CI_START="0.048510697731429714" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.7121024875250384" LOG_CI_START="-1.3141624788530009" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="1404" O_E="0.0" SE="1.1902380714238083" STUDY_ID="STD-Cashman-1961" TOTAL_1="6" TOTAL_2="6" VAR="1.4166666666666665" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.757050577673323" CI_START="0.02266915250163594" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.4404447332450383" LOG_CI_START="-1.6445647159009629" LOG_EFFECT_SIZE="-0.6020599913279624" METHOD="MH" MODIFIED="2008-07-03 12:16:24 +0100" MODIFIED_BY="Helen Collins" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.25767456073601214" Q="0.0" RANDOM="NO" SCALE="61.29850202948026" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0" Z="1.1319046060137772">
<NAME>premorbid intelligence level, Mill Hill vocabulary scale (change from baseline)</NAME>
<GROUP_LABEL_1>procaine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours procaine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.757050577673323" CI_START="0.02266915250163594" DF="0" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="0.4404447332450383" LOG_CI_START="-1.6445647159009629" LOG_EFFECT_SIZE="-0.6020599913279624" NO="1" P_CHI2="1.0" P_Z="0.25767456073601214" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0" Z="1.1319046060137772">
<NAME>gerioptil H3 12 injections/1 month</NAME>
<DICH_DATA CI_END="2.757050577673323" CI_START="0.02266915250163594" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4404447332450383" LOG_CI_START="-1.6445647159009629" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="1405" O_E="0.0" SE="1.224744871391589" STUDY_ID="STD-Cashman-1961" TOTAL_1="6" TOTAL_2="6" VAR="1.5" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.833174082253265" CI_START="0.0019203669846197147" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.04" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="-0.07926424821716153" LOG_CI_START="-2.7166157691269137" LOG_EFFECT_SIZE="-1.3979400086720375" METHOD="MH" MODIFIED="2008-07-03 12:16:34 +0100" MODIFIED_BY="Helen Collins" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.037730049636099106" Q="0.0" RANDOM="NO" SCALE="592.850241693342" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0" Z="2.077775410537367">
<NAME>overall changes from baseline</NAME>
<GROUP_LABEL_1>procaine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours procaine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.833174082253265" CI_START="0.0019203669846197147" DF="0" EFFECT_SIZE="0.04" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="-0.07926424821716153" LOG_CI_START="-2.7166157691269137" LOG_EFFECT_SIZE="-1.3979400086720375" NO="1" P_CHI2="1.0" P_Z="0.037730049636099106" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0" Z="2.077775410537367">
<NAME>gerioptil H3 12 injections/1 month</NAME>
<DICH_DATA CI_END="0.833174082253265" CI_START="0.0019203669846197147" EFFECT_SIZE="0.04" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="-0.07926424821716153" LOG_CI_START="-2.7166157691269137" LOG_EFFECT_SIZE="-1.3979400086720375" ORDER="1406" O_E="0.0" SE="1.5491933384829668" STUDY_ID="STD-Cashman-1961" TOTAL_1="6" TOTAL_2="6" VAR="2.4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2008-07-03 12:16:53 +0100" MODIFIED_BY="Helen Collins" NO="4">
<NAME>Procaine vs placebo</NAME>
<DICH_OUTCOME CHI2="0.011331678337814632" CI_END="25.015491432653647" CI_START="2.1287979683919214" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="7.297460334949317" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="1.3982090390760458" LOG_CI_START="0.32813444707668504" LOG_EFFECT_SIZE="0.8631717430763655" METHOD="MH" MODIFIED="2008-07-03 12:16:53 +0100" MODIFIED_BY="Helen Collins" NO="1" P_CHI2="0.9152250426994775" P_Q="0.0" P_Z="0.0015669197907676167" Q="0.0" RANDOM="NO" SCALE="43.15857937591307" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="208" TOTAL_2="207" WEIGHT="100.0" Z="3.1619955123714365">
<NAME>total adverse events</NAME>
<GROUP_LABEL_1>procaine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours procaine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="68.59870524196872" CI_START="0.9398348417770652" DF="0" EFFECT_SIZE="8.029411764705882" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="1.8363159187450178" LOG_CI_START="-0.02694845874801617" LOG_EFFECT_SIZE="0.9046837299985009" NO="1" P_CHI2="1.0" P_Z="0.05700533276874918" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="31.280299691494047" Z="1.9032699273542026">
<NAME>number of patients with at least one adverse event during procaine 10 ml/day after 30 days</NAME>
<DICH_DATA CI_END="68.59870524196872" CI_START="0.9398348417770652" EFFECT_SIZE="8.029411764705882" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.8363159187450178" LOG_CI_START="-0.02694845874801617" LOG_EFFECT_SIZE="0.9046837299985009" ORDER="1407" O_E="0.0" SE="1.0944907186468285" STUDY_ID="STD-Balaceanu-1989" TOTAL_1="41" TOTAL_2="40" VAR="1.1979099332040508" WEIGHT="31.280299691494047"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="31.362245187189615" CI_START="1.5464860765139086" DF="0" EFFECT_SIZE="6.964285714285714" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="2" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="1.4964071457695531" LOG_CI_START="0.18934601427104433" LOG_EFFECT_SIZE="0.8428765800202989" NO="2" P_CHI2="1.0" P_Z="0.011477312530503724" STUDIES="1" TAU2="0.0" TOTAL_1="167" TOTAL_2="167" WEIGHT="68.71970030850595" Z="2.5278201614917553">
<NAME>withdrawals due to adverse event during the treatment with procaine (KH3) 50 mg/day 2 years</NAME>
<DICH_DATA CI_END="31.36224518718963" CI_START="1.5464860765139083" EFFECT_SIZE="6.964285714285714" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="2" LOG_CI_END="1.4964071457695534" LOG_CI_START="0.18934601427104428" LOG_EFFECT_SIZE="0.8428765800202989" ORDER="1408" O_E="0.0" SE="0.767774178699173" STUDY_ID="STD-Hall-1983" TOTAL_1="167" TOTAL_2="167" VAR="0.5894771894771895" WEIGHT="68.71970030850595"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-04-28 12:42:57 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2010-04-28 12:39:18 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-04-28 12:09:43 +0100" MODIFIED_BY="[Empty name]">Sources searched and search strategies used</TITLE>
<APPENDIX_BODY MODIFIED="2010-04-28 12:39:18 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="12">
<TR>
<TH>
<P>Source</P>
</TH>
<TH>
<P>Search strategy</P>
</TH>
</TR>
<TR>
<TD>
<P>Medline (Ovid SP)</P>
</TD>
<TD>
<P>1. exp Dementia/</P>
<P>2. Delirium/</P>
<P>3. Wernicke Encephalopathy/</P>
<P>4. Delirium, Dementia, Amnestic, Cognitive Disorders/</P>
<P>5. dement*.mp.</P>
<P>6. alzheimer*.mp.</P>
<P>7. (lewy* adj2 bod*).mp.</P>
<P>8. deliri*.mp.</P>
<P>9. (chronic adj2 cerebrovascular).mp.</P>
<P>10. ("organic brain disease" or "organic brain syndrome").mp.</P>
<P>11. ("normal pressure hydrocephalus" and "shunt*").mp.</P>
<P>12. "benign senescent forgetfulness".mp.</P>
<P>13. (cerebr* adj2 deteriorat*).mp.</P>
<P>14. (cerebral* adj2 insufficient*).mp.</P>
<P>15. (pick* adj2 disease).mp.</P>
<P>16. (creutzfeldt or jcd or cjd).mp.</P>
<P>17. huntington*.mp.</P>
<P>18. binswanger*.mp.</P>
<P>19. korsako*.mp.</P>
<P>20. or/1-19</P>
<P>21. ((cognit* or memory* or mental*) adj4 (declin* or impair* or los* or deteriorat*)).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]</P>
<P>22. ((cognit* or memory* or mental*) adj4 (improv* or function* or process*)).mp.</P>
<P>23. (healthy or elderly or aged).mp.</P>
<P>24. Aged/</P>
<P>25. or/21-24</P>
<P>26. 20 or 25</P>
<P>27. gerovital.mp.</P>
<P>28. aslavital.mp.</P>
<P>29. procain*.mp.</P>
<P>30. exp *Procaine/</P>
<P>31. KH3.mp.</P>
<P>32. novocain*.mp.</P>
<P>33. GH3.mp.</P>
<P>34. trofibial.mp.</P>
<P>35. "Zell H3".mp.</P>
<P>36. Vitacel.mp.</P>
<P>37. GH7.mp.</P>
<P>38. "Ultimate 9".mp.</P>
<P>39. or/27-38</P>
<P>40. 26 and 39</P>
<P>41. randomized controlled trial.pt.</P>
<P>42. controlled clinical trial.pt.</P>
<P>43. randomized.ab.</P>
<P>44. placebo.ab.</P>
<P>45. drug therapy.fs.</P>
<P>46. randomly.ab.</P>
<P>47. trial.ab.</P>
<P>48. groups.ab.</P>
<P>49. or/41-48</P>
<P>50. (animals not (humans and animals)).sh.</P>
<P>51. 49 not 50</P>
<P>52. 40 and 51</P>
<P>53. (2007* or 2008* or 2009* or 2010*).ed.</P>
<P>54. 52 and 53</P>
</TD>
</TR>
<TR>
<TD>
<P>EMBASE (Ovid SP)</P>
</TD>
<TD>
<P>1. exp dementia/</P>
<P>2. Lewy body/</P>
<P>3. delirium/</P>
<P>4. Wernicke encephalopathy/</P>
<P>5. cognitive defect/</P>
<P>6. dement*.mp.</P>
<P>7. alzheimer*.mp.</P>
<P>8. (lewy* adj2 bod*).mp.</P>
<P>9. deliri*.mp.</P>
<P>10. (chronic adj2 cerebrovascular).mp.</P>
<P>11. ("organic brain disease" or "organic brain syndrome").mp.</P>
<P>12. "supranuclear palsy".mp.</P>
<P>13. ("normal pressure hydrocephalus" and "shunt*").mp.</P>
<P>14. "benign senescent forgetfulness".mp.</P>
<P>15. (cerebr* adj2 deteriorat*).mp.</P>
<P>16. (cerebral* adj2 insufficient*).mp.</P>
<P>17. (pick* adj2 disease).mp.</P>
<P>18. (creutzfeldt or jcd or cjd).mp.</P>
<P>19. huntington*.mp.</P>
<P>20. binswanger*.mp.</P>
<P>21. korsako*.mp.</P>
<P>22. CADASIL.mp.</P>
<P>23. or/1-22</P>
<P>24. ((cognit* or memory* or mental*) adj4 (declin* or impair* or los* or deteriorat*)).mp.</P>
<P>25. ((cognit* or memory* or mental*) adj4 (improv* or function* or process*)).mp.</P>
<P>26. (healthy or elderly or aged).mp.</P>
<P>27. aged/</P>
<P>28. or/24-27</P>
<P>29. 23 or 28</P>
<P>30. gerovital.mp.</P>
<P>31. aslavital.mp.</P>
<P>32. procain*.mp.</P>
<P>33. exp *procaine/</P>
<P>34. KH3.mp.</P>
<P>35. novocain*.mp.</P>
<P>36. GH3.mp.</P>
<P>37. trofibial.mp.</P>
<P>38. "Zell H3".mp.</P>
<P>39. Vitacel.mp.</P>
<P>40. GH7.mp.</P>
<P>41. "Ultimate 9".mp.</P>
<P>42. or/30-41</P>
<P>43. 30 and 42</P>
<P>44. clinical trial/</P>
<P>45. randomized controlled trial/</P>
<P>46. random*.ti,ab.</P>
<P>47. placebo.ab.</P>
<P>48. groups.ab.</P>
<P>49. "control group".ab.</P>
<P>50. or/44-49</P>
<P>51. 43 and 50</P>
<P>52. (2007* or 2008* or 2009* or 2010*).em.</P>
<P>53. 51 and 52</P>
</TD>
</TR>
<TR>
<TD>
<P>PsycINFO (Ovid SP)</P>
</TD>
<TD>
<P>1. exp Dementia/</P>
<P>2. exp Delirium/</P>
<P>3. exp Huntingtons Disease/</P>
<P>4. exp Kluver Bucy Syndrome/</P>
<P>5. exp Wernickes Syndrome/</P>
<P>6. exp Cognitive Impairment/</P>
<P>7. dement*.mp.</P>
<P>8. alzheimer*.mp.</P>
<P>9. (lewy* adj2 bod*).mp.</P>
<P>10. deliri*.mp.</P>
<P>11. (chronic adj2 cerebrovascular).mp.</P>
<P>12. ("organic brain disease" or "organic brain syndrome").mp.</P>
<P>13. "supranuclear palsy".mp.</P>
<P>14. ("normal pressure hydrocephalus" and "shunt*").mp.</P>
<P>15. "benign senescent forgetfulness".mp.</P>
<P>16. (cerebr* adj2 deteriorat*).mp.</P>
<P>17. (cerebral* adj2 insufficient*).mp.</P>
<P>18. (pick* adj2 disease).mp.</P>
<P>19. (creutzfeldt or jcd or cjd).mp.</P>
<P>20. huntington*.mp.</P>
<P>21. binswanger*.mp.</P>
<P>22. korsako*.mp.</P>
<P>23. ("parkinson* disease dementia" or PDD or "parkinson* dementia").mp.</P>
<P>24. or/1-23</P>
<P>25. ((cognit* or memory* or mental*) adj4 (declin* or impair* or los* or deteriorat*)).mp.</P>
<P>26. ((cognit* or memory* or mental*) adj4 (improv* or function* or process*)).mp.</P>
<P>27. (healthy or elderly or aged).mp.</P>
<P>28. or/25-27</P>
<P>29. 24 or 28</P>
<P>30. gerovital.mp.</P>
<P>31. aslavital.mp.</P>
<P>32. procain*.mp.</P>
<P>33. exp *Procaine/</P>
<P>34. KH3.mp.</P>
<P>35. novocain*.mp.</P>
<P>36. GH3.mp.</P>
<P>37. trofibial.mp.</P>
<P>38. "Zell H3".mp.</P>
<P>39. Vitacel.mp.</P>
<P>40. GH7.mp.</P>
<P>41. "Ultimate 9".mp.</P>
<P>42. or/30-41</P>
<P>43. 29 and 42</P>
<P>44. (2007* or 2008* or 2009* or 2010*).up.</P>
<P>45. 43 and 44</P>
</TD>
</TR>
<TR>
<TD>
<P>CINAHL (EbscoHOST)</P>
</TD>
<TD>
<P>S1 (MH "Denentia+")</P>
<P>S2 (MH "Delirium") or (MH "Delirium, Dementia, Amnestic, Cognitive Disorders")</P>
<P>S3 (MH "Wernicke's Encephalopathy")</P>
<P>S4 TX dement*</P>
<P>S5 TX alzheimer*</P>
<P>S6 TX lewy* N2 bod*</P>
<P>S7 TX deliri*</P>
<P>S8 TX chronic N2 cerebrovascular</P>
<P>S9 TX "organic brain disease" or "organic brain syndrome"</P>
<P>S10 TX "normal pressure hydrocephalus" and "shunt"</P>
<P>S11 TX "benign senescent forgetfulness"</P>
<P>S12 TX cerebr* N2 deteriorat*</P>
<P>S13 TX cerebral* N2 insufficient*</P>
<P>S14 TX pick* N2 disease</P>
<P>S15 TX creutzfeldt or jcd or cjd</P>
<P>S16 TX huntington*</P>
<P>S17 TX binswanger*</P>
<P>S18 TX korsako*</P>
<P>S19 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18  </P>
<P>S20 TX cognit* N4 improv*  </P>
<P>S21 TX cognit* N4 function*  </P>
<P>S22 TX cognit* N4 process*  </P>
<P>S23 TX healthy  </P>
<P>S24 TX elderly  </P>
<P>S25 TX aged  </P>
<P>S26 (MH "Aged")  </P>
<P>S27 S20 or S21 or S22 or S23 or S24 or S25 or S26  </P>
<P>S28 S19 or S27  </P>
<P>S29 TX gerovital  </P>
<P>S30 TX aslavital  </P>
<P>S31 TX procain*  </P>
<P>S32 (MM "Procaine")  </P>
<P>S33 TX KH3  </P>
<P>S34 TX novocain*  </P>
<P>S35 TX GH3  </P>
<P>S36 TX trofibial  </P>
<P>S37 TX "Zell H3"  </P>
<P>S38 TX GH7  </P>
<P>S39 TX Vitacel  </P>
<P>S40 S29 or S30 or S31 or S32 or S33 or S34 or S35 or S36 or S37 or S38 or S39 or S40  </P>
<P>S42 S28 and S41  </P>
<P>S43 EM 2007  </P>
<P>S44 EM 2008  </P>
<P>S45 EM 2009  </P>
<P>S46 EM 2010  </P>
<P>S47 S43 or S44 or S45 or S46  </P>
<P>S48 S42 and S47  </P>
<P>S49 (MH "Clinical Trials+")  </P>
<P>S50 AB random*  </P>
<P>S51 AB groups  </P>
<P>S52 TI trial  </P>
<P>S53 AB placebo  </P>
<P>S54 AB "control group"  </P>
<P>S55 S49 or S50 or S51 or S52 or S53 or S54  </P>
<P>S56 S48 and S55  </P>
<P/>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>CENTRAL</P>
</TD>
<TD>
<P>#1  MeSH descriptor Dementia explode all trees</P>
<P>#2  MeSH descriptor Delirium, this term only</P>
<P>#3 MeSH descriptor Wernicke Encephalopathy, this term only</P>
<P>#4 MeSH descriptor Delirium, Dementia, Amnestic, Cognitive Disorders, this term only</P>
<P>#5  dement*</P>
<P>#6  alzheimer*</P>
<P>#7  "lewy* bod*"</P>
<P>#8  deliri*</P>
<P>#9  "chronic cerebrovascular"</P>
<P>#10  "organic brain disease" or "organic brain syndrome"</P>
<P>#11 "normal pressure hydrocephalus" and "shunt*"</P>
<P>#12 "benign senescent forgetfulness"</P>
<P>#13 "cerebr* deteriorat*"</P>
<P>#14 "cerebral* insufficient*"</P>
<P>#15 "pick* disease"</P>
<P>#16 creutzfeldt or jcd or cjd</P>
<P>#17 huntington*</P>
<P>#18 binswanger*</P>
<P>#19                korsako*</P>
<P>#20 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19)</P>
<P>#21 (cognit* or memory* or mental*) NEAR/4 (declin* or impair* or los* or deteriorat*)</P>
<P>#22 (cognit* or memory* or mental*) NEAR/4 (improv* or function* or process*)</P>
<P>#23 healthy or elderly or aged</P>
<P>#24 (#21 OR #22 OR #23)</P>
<P>#25 (#20 OR #24)</P>
<P>#26 gerovital</P>
<P>#27 aslavital</P>
<P>#28 procain*</P>
<P>#29 MeSH descriptor Procaine explode all trees</P>
<P>#30 KH3</P>
<P>#31 novocain*</P>
<P>#32 GH3</P>
<P>#33 trofibial</P>
<P>#34 "Zell H3"</P>
<P>#35 Vitacel</P>
<P>#36 GH7</P>
<P>#37 "Ultimate 9"</P>
<P>#38 (#26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37)</P>
<P>#39 (#25 AND #38)</P>
<P>#40 (#39), from 2007 to 2010</P>
</TD>
</TR>
<TR>
<TD>
<P>LILACS</P>
</TD>
<TD>
<P>dement$ OR demenc$ OR alzheimer$ OR cognit$ OR cognic$ OR elderly OR anciano OR idoso OR healthy OR saludable OR saudavel OR conhecimento [Words] and procain$ OR gerovital OR aslavital OR KH3 OR novocain$ OR GH3 OR trofibial OR "Zell H3" OR Vitacel OR GH7 OR "Ultimate 9" [Words]</P>
</TD>
</TR>
<TR>
<TD>
<P>ALOIS</P>
</TD>
<TD>
<P>Advanced search: [Intervention: procaine]</P>
</TD>
</TR>
<TR>
<TD>
<P>ClinicalTrials.gov</P>
</TD>
<TD>
<P>Interventional Studies | gerovital OR aslavital OR procaine OR KH3 OR novocaine OR GH3 OR trofibial OR zell OR vitacel OR gh7 OR ultimate 9 | Adult Senior | received from 01/01/2007 to 04/16/2010</P>
</TD>
</TR>
<TR>
<TD>
<P>Science Citation Index and Conference Proceedings (Web of Knowledge)</P>
</TD>
<TD>
<P>Topic=(dement* OR Alzheimer* OR "Lewy body" OR arteriosclerosis OR "Huntington* disease" OR "Kluver Bucy" OR "Pick disease" OR delirium OR "cerebrovascular disorder*" OR "Wernicke encephalopathy" OR "Korsakoff psychosis" OR cognit* OR "cerebr* deteriorat*" OR "cerebr* insufficien*" OR healthy OR elderly OR aged) AND Topic=(gerovital OR aslavital OR procain* OR KH3 OR novocain* OR GH3 OR trofibial OR "Zell H3" OR Vitacel OR GH7 OR "Ultimate 9") AND Topic=(random* OR trial* OR placebo OR group*)</P>
<P>Timespan=2007-2010. Databases=SCI-EXPANDED, SSCI, A&amp;HCI, CPCI-S.</P>
</TD>
</TR>
<TR>
<TD>
<P>ICTRP Search Portal (WHO Portal)</P>
</TD>
<TD>
<P>(Condition: dementia OR alzheimers OR alzheimer OR healthy OR elderly) AND (gerovital OR aslavital OR procaine OR KH3 OR novocaine OR GH3 OR trofibial OR zell OR vitacel OR gh7 OR ultimate 9) AND (date rec: 01/01/2007 ? 16/04/2010)</P>
</TD>
</TR>
<TR>
<TD>
<P>UMIN</P>
</TD>
<TD>
<P>Free keyword [each term entered separately]: gerovital OR aslavital OR procaine OR KH3 OR novocaine OR GH3 OR trofibial OR zell OR vitacel OR gh7 OR ultimate 9</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2010-04-28 12:42:57 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-04-28 12:42:52 +0100" MODIFIED_BY="[Empty name]">Previous search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2010-04-28 12:42:57 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="6">
<TR>
<TH>
<P>Source and date searched</P>
</TH>
<TH>
<P>Search strategy</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MEDLINE (1966-2007/September week 1)</P>
</TD>
<TD>
<P>#1 gerovital* or aslavital* or procain* or KH3 or novocain* or GH3 or trofibial or "Zell H3" or Vitacel* or GH7 or "Ultimate 9"<BR/>#2 explode "Procaine"/ all subheadings<BR/>#3 #1 or #2<BR/>#4 (randomi?ed in TI) or (randomi?ed in PT)<BR/>#5 placebo* or double-blind*<BR/>#6 #4 or #5<BR/>#7 #3 and #6<BR/>#8 ((TG=animals) not (TG=humans)) and (TG=animals)<BR/>#9 #7 not #8</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EMBASE (1981-2007/week 37)</P>
</TD>
<TD>
<P>#1 gerovital* or aslavital* or procain* or KH3 or novocain* or GH3 or trofibial or "Zell H3" or Vitacel* or GH7 or "Ultimate 9"<BR/>#2 explode "Procaine"/ all subheadings<BR/>#3 #1 or #2<BR/>#4 (randomi?ed in TI) or (randomi?ed in PT)<BR/>#5 placebo* or double-blind*<BR/>#6 #4 or #5<BR/>#7 #3 and #6<BR/>#8 anesthesia or (arrhythmia* in TI)<BR/>#9 #7 not #8<BR/>#10 anesthesia or arrhythmia* or (antiarrhymi* in TI, DEM, DER)<BR/>#11 #7 not #10<BR/>#12 "atrial fibrillation" in TI, AB<BR/>#13 #11 not #12<BR/>#14 pain in DEM<BR/>#15 #13 not #14<BR/>#16 #15 not incontinen*<BR/>#17 #16 and (cognit* or QOL or "quality of life" or memory*)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PsycINFO (1806-2007/September week 1)</P>
</TD>
<TD>
<P>#1 gerovital* or aslavital* or procain* or KH3 or novocain* or GH3 or trofibial or "Zell H3" or Vitacel* or GH7 or "Ultimate 9"<BR/>#2 "Procaine-" in MJ,MN<BR/>#3 #1 or #2<BR/>#4 random* or placebo* or double-blind* or "double blind*"<BR/>#5 #3 and #4</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CINAHL (1982-2007/September week 1)</P>
</TD>
<TD>
<P>#1 gerovital* or aslavital* or procain* or KH3 or novocain* or GH3 or trofibial or "Zell H3" or Vitacel* or GH7 or "Ultimate 9"<BR/>#2 explode "Procaine"/ all subheadings<BR/>#3 #1 or #2<BR/>#4 explode "Clinical-Trials"/ without-subheadings , adverse-effects , classification , economics , education , ethical-issues , equipment-and-supplies , evaluation , history , immunology , legislation-and-jurisprudence , methods , organizations , standards , trends , therapeutic-use , utilization / without-subheadings , in-adolescence , in-adulthood , in-infancy-and-childhood , in-old-age , in-pregnancy , in-utero<BR/>#5 #3 and #4</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CENTRAL (September: issue 3/2007)</P>
</TD>
<TD>
<P>#1 gerovital* or aslavital* or procain* or KH3 or novocain* or GH3 or trofibial or "Zell H3" or Vitacel* or GH7 or "Ultimate 9"<BR/>#2 explode "Procaine"/ all subheadings<BR/>#3 #1 or #2<BR/>#4 anesthesia or arrhythmia* or antiarrhymi*<BR/>#5 #3 not #4<BR/>#6 "atrial fibrillation"<BR/>#7 #5 not #6<BR/>#8 pain<BR/>#9 #7 not #8<BR/>#10 #9 not incontinen*<BR/>#11 #10 and (cognit* or QOL or "quality of life" or memory*)</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>